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1. Zusammenfassung 
Heutzutage basiert die Therapie des Lungenkarzinoms und des Pleuramesothelioms 
meist auf Cisplatin-haltiger Kombinationstherapie. Bei der Mehrzahl der Patienten 
führt dies zu einer vorübergehenden Hemmung des Tumorwachstums, mit der Zeit 
entwickelt sich aber eine Resistenz des Tumors gegenüber Cisplatin. Studien in 
Modelsystemen zeigen, dass die Translesionssynthese (TLS) eine entscheidende 
Rolle in der Entwicklung der Cispatinresistenz spielt. Das ursprüngliche Ziel dieser 
PhD Arbeit war die Rolle von REV3, der katalytische Untereinheit der TLS 
Polymerase zeta (Pol ζ), in der Resistenzentwicklung genauer zu charakterisieren.  
Die Hypothese, inwiefern die Inaktivierung der REV3 Exprimierung die Cisplatin-
induzierte Mutationsrate beeinflusst, wurde überprüft. Dabei wurde entdeckt, dass 
die Inhibierung der REV3 Exprimierung auch ohne Zugabe von Cisplatin zu einem 
reduzierten Wachstum von Krebszellen führt, wohingegen Zellen kultiviert von nicht-
malignem Gewebe deutlich weniger beeinträchtigt sind. Zu diesem Zeitpunkt wurde 
entschieden, diese Beobachtung zu verifizieren und die Ursachen zu entschlüsseln.  
Es wurde in mehreren verschiedenen Krebszelllinien bestätigt, dass die Inaktivierung 
der REV3 Exprimierung in einer Reduktion des Zellwachstums resultiert. In der Folge 
wurde gezeigt, dass die Inhibierung der REV3 Exprimierung zu einer Akkumulierung 
bleibender DNA Schäden in Krebszellen führt und zu einer ATM-abhängigen 
Aktivierung des sogenannten DNA Schaden Reparatur Signalweges führt. Die 
Inaktivierung der REV3 Exprimierung in Krebszellen mit p53 Wildtyp lässt die Zellen 
im G1 Zellzyklus arretieren und induziert Seneszenz. Dies wurde durch die 
Anhäufung des Zellzyklus-Hemmers p21 und einer erhöhten Seneszenz-assoziierten 
(SA)-β-Galaktosidase Aktivität verifiziert. 
In Krebszellen mit fehlender oder reduzierter p53 Funktion resultiert die Inhibierung 
der REV3 Exprimierung in einer Hemmung des Zellwachstums und in einem G2/M 
Zellzyklusarrest. Ein kleiner Teil der Zellen wird nicht arretiert, was zu einer 
numerischen Chromosomenaberration, der sogenannten Aneuploidie führt. 
Somit konnte mit diesen Resultaten zum ersten Mal belegen werden, dass die 
Hemmung einer TLS Pol per se zu einer spezifischen Beeinträchtigung von 
Krebszellen führt. Demzufolge wird postuliert, dass die Hemmung von REV3 ein 
möglicher Ansatz für eine Krebs-spezifische Therapie darstellen könnte.  
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2. Summary 
Today, the therapy of lung cancer and malignant pleural mesothelioma is based on 
cisplatin as part of a multimodality approach. Despite an initial response to 
chemotherapy in a proportion of patients, all will ultimately develop chemotherapy 
resistant disease. Studies done in model systems indicated that functional 
translesion synthesis (TLS) is a major contributor to the development of cisplatin 
resistance. The initial aim of the PhD thesis was to elucidate the involvement of 
REV3, the catalytic subunit of TLS Polymerase zeta (Pol ζ) in the development of 
chemotherapy resistance.  
Surprisingly, while investigating how inhibition of REV3 expression affects cisplatin-
induced mutagenesis, it was found that inhibition of REV3 expression per se 
suppresses colony formation of cancer cells whereas cells cultured from non–
malignant tissue were less affected. At this time, it was decided to further investigate 
these findings.  
Further, it was confirmed that inhibition of REV3 expression in various cancer cell 
lines leads to a growth inhibition. In addition, it was shown that inhibition of REV3 
expression leads to an accumulation of persistent DNA damage, subsequently 
leading to the activation of the ATM-dependent DNA damage response (DDR) 
cascade. The inhibition of REV3 expression in p53-proficient cancer cell lines results 
in a G1-arrest and induction of senescence as indicated by the accumulation of p21 
and an increase in senescence-associated (SA)-β-Galactosidase activity. In contrast, 
the inhibition of REV3 expression in p53-deficient or p53-knockout cancer cells 
results in a growth inhibition and a G2/M-arrest whereas a small fraction of the p53-
deficient or p53-knockout cancer cells can overcome the G2/M-arrest, which results in 
mitotic slippage and aneuploidy.  
It is shown for the first time that inhibition of a TLS Pol confers synthetic 
sickness/lethality specifically in cancer cells. These findings reveal that inhibition 
REV3 expression per se suppresses cancer cell growth whereas normal cells are 
less affected, thus identifying REV3 as a potential target for a cancer-specific 
therapy. 
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3. Introduction 
3.1. DNA damage overview 
Genomic information is stored as deoxyribonucleic acid (DNA) in every living 
organism and needs to be protected and maintained to guarantee genomic integrity. 
Each of the 1013 cells of the human body contains 30000-40000 genes encoded by 
3x109 base pairs of the DNA [(1, 2) and reviewed in (3)]. The integrity of the DNA is 
constantly threatened either by spontaneous decay or by damage induced by 
endogenous and environmental sources, respectively. In addition, the accurate 
doubling of the DNA is an essential step carried out by the DNA replication 
machinery but errors during this process can also compromise the genomic integrity. 
For example, damaged DNA, which cannot be replicated by the high fidelity 
replicative DNA Pols, can lead to stalled replication forks and subsequent replication 
fork breakdown results in chromosomal instability. 
The most frequent DNA alterations by endogenous sources result from spontaneous 
depurination/ depyriminidation processes and deamination of the base cytosine to 
uracil. Oxidative stress can lead to the generation of reactive oxygen species (ROS), 
which induce base modification such as 7, 8-dihydro-8-oxoguanine (8-oxo-G) and 
Thymine glycol (Tg) [reviewed in (4, 5)].  
The most abundant environmental source of DNA damage is ultraviolet light (UV), 
which can induce nucleotide dimerization such as (6-4) photoproducts and 
cyclobutane pyrimidine dimers (CPDs) [reviewed in (6)]. 
The chemical agent cisplatin used for therapeutical treatment of lung cancer and 
malignant pleural mesothelioma forms DNA intra- and interstrand cross links (ICL), 
which can lead to a blockage of the DNA replication machinery (7). Benzo(α)pyrene 
is a major compound of tobacco smoke and forms, upon metabolic activation, a 
covalent Benzo(α)pyrene-guanine (BP-G) DNA adduct, which frequently mispairs 
during DNA replication with adenine therefore leading to guanine:thymine 
transversions (8). 
To counteract the tens of thousands of lesions per genome per day, cells evolved a 
complex and interplaying system, the so-called DDR [reviewed in (9, 10)]. During 
DDR, DNA lesions are detected, leading to the activation of a signal cascade 
resulting either in the repair or the tolerance of the DNA damage, thereby regulating 
cell faith after genomic insult [reviewed in (4)] (Fig.1). 
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Fig.1 DNA damage induced by spontaneous decay or endogenous and 
environmental sources can either by repaired or tolerated [Adapted from reference 
(11)]. For details see text. 
 
3.2. DNA damage response (DDR) 
DNA damage induction results in the activation of a molecular cascade, e.g. the 
DDR, which consists of DNA damage sensors, transducers and effectors.  
Induction of double-strand breaks (DSBs) triggers the ataxia telangiectasia mutated 
(ATM)-dependent DDR (Fig.2) whereas the formation of replication protein A coated 
single-stranded DNA (ssDNA) leads to the activation of the ataxia telangiectasia and 
RAD3 related (ATR)-dependent DDR (Fig.3).  
Upon DSB induction, DNA damage sensors including the MRN (MRE11, NBS1 and 
RAD50) complex and the KU70/80 dimer activate the phosphoinositide-3-kinase-
related protein kinases (PIKKs) ATM or DNA-dependent protein kinase catalytic 
subunit (DNA-PKcs), respectively [reviewed in (12)]. The activated ATM homodimer 
undergoes autophosphorylation leading to the dissociation of the homodimer (13) 
and the subsequent phosphorylation of the histone variant H2AX at serine 139 
(γH2AX) adjacent to the DSB (14). Phosphorylated γH2AX recruits the mediator of 
DNA damage checkpoint 1 (MDC1) [reviewed in (15)], breast cancer 1 (BRCA1) 
[reviewed in (16)] and p53 binding protein 1 (53BP1) [reviewed in (17)] thereby 
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accumulating additional MRN complexes resulting in a positive feedback loop, e.g. 
increased local ATM activity and γH2AX phosphorylation along the chromatin 
[reviewed in (18)]. ATM further phosphorylates numerous downstream substrates 
including the checkpoint kinase 2 (CHK2) (19), which activates the transcription 
factor p53 by phosphorylation (20). Beside the key role of p53 regulating cellular 
processes such as apoptosis, senescence and DNA repair [reviewed in (21)], the p53 
also regulates the cell cycle progression via accumulation of the cyclin-dependent 
kinase inhibitor p21. Accumulated p21 inhibits the cyclinE/CDK2 and thereby 
blocking the G1/S transition (22). Prolonged activation of p21 after DNA damage is 
associated with a terminal proliferation arrest, e.g. senescence. In the absence of 
p53, damaged cells are not able to arrest in the G1/S phase (23) (Fig.2). 
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Fig.2 Schematic diagram of the DDR cascade activated by the induction of DNA 
double strand breaks. Blue boxes refer to sensors, light blue boxes to transducers 
and red boxes to effectors. For details see text. 
 
Replication fork blockage can result in the generation of replication protein A (RP-A) 
coated ssDNA leading to the recruitment of the heterodimeric complex (ATR) with its 
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DNA binding subunit ATR interacting protein (ATRIP) (24). The recruitment of ATR-
ATRIP at the site of the DNA lesion is boosted by the mediators RAD17/ replication 
factor C2-5 (RF-C2-5) and the RAD9-HUS1-RAD1 (9-1-1) complex and causes the 
local phosphorylation of γH2AX (25). Additionally, ATR activity is stimulated by the 
DNA topoisomerase-II-binding protein (TOPBP1). Phosphorylation of checkpoint 
kinase 1 (CHK1) is mediated by ATR (25) and needs the stimulation by claspin 
[reviewed in (26)]. Activated CHK1 triggers ubiquitin- and proteasome-dependent 
degradation of cell division cycle 25 (Cdc25) phosphatases, which subsequently 
leads to a cell cycle arrest (Fig.3).  
The induction of a cell cycle arrest allows the cell to induce repair and/or tolerance 
mechanisms to maintain genomic stability thereby preventing tumorigenesis [(27, 28) 
and reviewed in (29)]. 
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Fig.3 Schematic diagram of the DDR cascade activated by the presence of single 
stranded DNA (ssDNA), which can be generated after DNA replication fork blockage. 
Blue boxes refer to sensors, light blue boxes to transducers and red boxes to 
effectors. For details see text. 
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The cellular DNA repair machinery consists of non-homologous end joining (NHEJ) 
and homologous recombination (HR) to repair double strand breaks, base excision 
repair (BER) to counteract modification of the nitrogenous bases, nucleotide excision 
repair (NER) to excise altered nucleotides such as 6-4 photoproducts and 
cyclobutane pyrimidine dimers (CPDs), mismatch repair (MMR) to exchange 
mispaired nucleotides and direct damage repair for reversal of alkylated nucleotides 
(Fig.1) [reviewed in (30)]. Although DNA repair processes are not as accurate as 
high-fidelity DNA replication, DNA repair is considered to be error-free compared to 
DNA damage tolerance mechanisms. 
Activation of the DNA damage tolerance mechanisms is mediated by modifications of 
proliferating cell nuclear antigen (PCNA). Monoubiquitinated PCNA activates the 
bypass of the DNA lesions by TLS Pols whereas the polyubiquitination of PCNA by 
RAD5 triggers the error-free DNA damage tolerance carried out by template 
switching including fork reversal or recombination past the lesion [reviewed in (31, 
32)]. TLS Pols can generate mutations by the incorporation of inaccurate nucleotides 
according to Watson-Crick base pairing thereby allowing DNA replication to bypass 
DNA lesions, which otherwise would block replication. The presence of error-prone 
TLS Pols reflects a trade-off between the maintenance of genomic integrity by 
avoiding replication fork breakdown and subsequent chromosomal instability and the 
occurrence of mutations on the nucleotide level by the DNA damage bypass reaction 
mediated by the TLS Pols. In addition, the low fidelity of TLS contributes to other 
essential cellular mechanisms, e.g. the TLS Pol ζ contributes directly to class switch 
recombination (CSR) and indirectly to somatic hypermutation (SHM) in the 
diversification process of immunoglobulin (IgG) (33). 
Alternatively, if the amount of DNA lesions are above a certain threshold or if the type 
of DNA lesion are irreparable for accurate repair or bypass, cells undergoes 
apoptosis or senescence due to constitutively activated DDR signaling thereby 
avoiding chromosomal instability and chromosomal aberrations that could lead to 
diseases including cancer. It remains still unclear what exactly determines the 
induction of senescence or apoptosis. It is discussed that the cell fate after DNA 
damage induction is not only dependent on the duration and nature of the DNA 
damage but is also dependent on the cell type and on extracellular signals. It was 
shown that cells undergo senescence due to the induction of severe or irreparable 
DNA damage that leads to the accumulation of persistent DNA damage (34). The 
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induction of senescence leads to an irreversible growth arrest of the cell and to the 
development of a complex senescence-associated secretory phenotype (SASP) that 
includes the secretion of cytokines such as IL-6. The initiation and maintenance of 
SASP needs the DDR factors ATM, NBS1 and CHK2 (34). It has to be further 
elucidated whether the activation of the SASP has a beneficial or detrimental effect 
on tumor growth. However, senescent cancer cells are unable to further proliferate 
and therefore the induction of senescence mirrors a break in tumor progression. 
 
4. Mammalian TLS Polymerases: state-of the art 
4.1. History and Discovery 
The first genes encoding for TLS Pol REV1 (encoding the TLS Pol Rev1) and REV3 
(encoding the catalytic subunit of TLS Pol ζ) were discovered and identified in 
Saccharomyces cerevisiae (S. cerevisiae) using a screen for reversionless (rev) 
mutants unable to revert an auxotropic marker after UV irradiation (35). A similar 
strategy lead to the discovery of UmuC in Escherichia coli (36) and REV7, the 
structural subunit of TLS Pol ζ, in S. cerevisiae (37).  
Other TLS Pols such as Pol η (eta; hRAD30A/XPV), Pol ι (iota; hRAD30B), Pol κ 
(kappa; DINB1) and Pol θ (theta; POLQ) were identified by searches for homologues 
of genes of previously identified TLS Pols such as REV1, umuC, dinB and mus308 
(38-41). The TLS Pol µ (mu) (42, 43) and Pol λ (lambda) were discovered and 
described more recently (42, 44). The most recently described TLS Pol ν (nu) was 
found due to homology with mus308 (45).  
The ability of TLS Pols to bypass DNA lesions, was firstly described for the yeast 
TLS Pol ζ (46). Together with yeast REV7, the structural subunit of the TLS Pol ζ 
(37), yeast REV3 mediates the bypass of Thymine-thymine cyclobutane pyrimidine 
dimers (TT-CPDs) (46).The property of Rev1 to inserts deoxycytidine 
monophosphate (dCMPs) opposite abasic sites was first described in yeast (47). 
Subsequently, the role of human TLS Pol ζ to bypass DNA lesions (48) and the 
function of human Rev1 as dCMP transferase opposite abasic sites (49) were 
proposed. The error free TT-CPD bypass activity of human TLS Pol η was 
discovered by the fact that xeroderma pigmentosum variant (XPV) patients show 
increased susceptibility to UV-induced skin cancer [reviewed (50)] and 
hypermutability (51) due to a defect of TLS Pol η. The human TLS Pol ι was shown to 
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be able to incorporate deoxynucleotides opposite the 3’ T of (6-4) photoproducts and 
abasic sites (52) and opposite N2-adducted guanine (53). The human TLS Pol κ 
protects cells against the lethal and mutagenic effects of benzo[a]pyrene 
incorporating the accurate nucleotide opposite the DNA adduct (54). The human TLS 
Pol θ was shown to be implicated in TLS synthesis and somatic hypermutation 
(SHM) (55-57). Moreover, the TLS Pol λ and TLS Pol µ are both implicated in V(d)J 
recombination (58, 59). Further, it was shown that TLS Pol ν is able to bypass 
thymine glycols (60). 
 
4.2. Fidelity and activation of TLS  
TLS Pols are optimized to bypass DNA lesions and are characterized by low fidelity 
DNA synthesis and lack the exonuclease proofreading activity thus generating 
mutations. The error rate of DNA replication Pols of the families A, B and C including 
correct incorporation of the nucleotide and the proofreading activity is between 10-6 
and 10-8. Auxiliary proteins such as PCNA and RP-A (61) and postreplicative MMR 
decrease the error rate to 10-8 and 10-10 . The error rate of the TLS Pols ranges from 
10-1 to 10-3 for replication of undamaged DNA. [reviewed in (62, 63)].  
Although the location in the tertiary structure consisting of palm, thumb and fingers is 
conserved among the different Pol families, the thumb and fingers are smaller in the 
TLS Pols (Fig.4). Compared to the DNA replication Pols where the fingers tightly bind 
the incoming dNTPs and make a conformational change upon correct Watson-Crick 
base pairing, the active site of TLS Pols is more open and less constrained to reject 
wrong paired base pairs. Therefore, TLS Pols are able to mediate the bypass 
reaction of non-coding DNA lesions. The additional little finger of the Y family TLS 
Pols supports the stabilization of the template DNA and influences fidelity and activity 
(64) (Fig.4). 
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Fig.4 Structural comparison of the Thermus aquaticus DNA Pol I of the A-family and 
TLS Pol η of the Y-family [reproduced from ref. (65)]. For details see text. 
 
A key event in the activation of TLS is the monoubiquitination of PNCA that encircles 
the DNA and achieves the TLS processivity. This event is proposed as a switch 
between DNA replication and TLS based on observations of the Y-family TLS Pols 
whereas TLS Pols bind to monoubiquitinated PCNA through the ubiquitin-binding 
domains such as the ubiquitin binding motif (UBM), the ubiquitin binding zinc finger 
(UBZ)] and a PCNA interacting peptide box (PIP) (66, 67). The monoubiquitination of 
PCNA is carried out by the RAD6-RAD18 complex upon replication fork stalling 
[reviewed in (31, 32)]. Moreover, a role of p53 via the PCNA-interacting domain of 
p21 has been proposed to mediate the activity of TLS Pols, together with the DNA 
damage induced monoubiquitination of PCNA at lysine 164 (68). 
An interplaying mechanism was proposed between the deubiquitinating enzyme 
USP1 and ubiquitination factors including RAD6 and RAD18. USP1 acts as a 
negative regulator, thus removing the ubiquitin residue from the monoubiquitinated 
PCNA to reduce the mutagenic effect by TLS Pols [reviewed in (69)]. 
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In addition to the discussed activation of either the error-free or the error-prone 
tolerance mechanisms upon DNA lesions, the question raised whether the regulation 
between DNA replication and the DNA damage tolerance (DDT) pathway is 
dependent on the cell cycle. It has been shown, that inappropriate expression of TLS 
Pol κ and Pol β in human cells leads to accumulation of mutations by competing with 
the high fidelity replicative DNA Pols. This finding indicated that the activation of high-
fidelity replicative Pols and TLS Pols has to be temporally regulated (70, 71) 
A model was proposed where the major function of TLS Pols is to allow replication to 
continue in the presence of DNA damage thereby allowing progression in S-phase 
(72). However, initial studies in yeast revealed that TLS Pols have a function beyond 
S-phase, the so called post replicative repair (PRR) (73).  
Moreover, other studies in yeast revealed that TLS Pols are also required for ICL 
repair during the G1 phase (74). 
Further, REV1 and PCNA, which regulate TLS activity, are also active outside S-
phase. In detail, REV1, which interacts and thereby regulates the activity of several 
TLS Pols is highly expressed in late S and early G2 in yeast (75). Ubiquitinated PCNA 
in human cells is stably bound to chromatin even after the lesion has been removed 
(76). Recently, a distinct role for REV1 and PCNA in the regulation of TLS was 
discussed using the chicken cell line DT40. It was shown, that REV1 plays a role for 
maintaining replication fork progression at damaged DNA and PCNA is required for 
postreplicative action (77). Additionally, studies in mammalian revealed that human 
REV3 is accumulated in G1 and at the G2/M transition in U2OS cells (78). However, 
recent findings in yeast revealed, that both error-prone TLS and error-free template 
switching takes place in G2/M phase after DNA replication (79).  
Taken together, the activation of the DDT pathway is regulated by the mono- or 
polyubiquitination of PCNA and the activation of REV1, which itself might be 
dependent on the stage of the cell cycle. More studies are needed to elucidate the 
exact details of the regulation of the DDT pathway. 
 
 
 
 
 
16 
4.3. TLS Polymerase families 
 
DNA Polymerase (encoding gene)Family Size (kDa)
Pol µ (POLM)X 55
REV 1 (REV1)Y 138
Pol η (POLH)Y 78
Pol κ (POLK)Y 99
Pol β (POLB)X 39 5’ dRP lyase activity 
X Pol λ (POLL)69 5’ dRP lyase activity 
N C
Pol θ (POLQ)A 290 3’ to 5’ exonuclease proofreading activity?5’ dRP lyase activity 
Helicase-like domain 5‘ deoxyribose phosphate (dRP) lyase domain TRFH motif Polymerase interacting region (PIR)
BRCT domain Ubiquitin binding zinc finger (UBZ) KIAA2022 PCNA interacting peptide (PIP)
Ubiquitin binding motif (UBM) CHK2 phosphorylation siteREV7 binding site Nuclear localization domain (NLD)
DNA polymerase domain AHDC1REV1 interacting region (RIR) 5‘dRP lyase activity
Pol ι (POLI)Y 80 5’ dRP lyase activity 
Pol ζ (REV3)B 353
Pol ν (POLN)A 100
 
Fig.5 Overview of TLS Pols [Adapted from ref. (65)]. For details see chapter 4.3. 
4.3.1. Family A: TLS Polymerases theta (θ) and nu (ν) 
4.3.1.1. TLS Pol θ 
The A family Pols consist of DNA Pol γ, TLS Pol ν and TLS Pol θ. TLS Pol θ was 
mapped on the chromosome locus 3q. The cDNA of TLS Pol θ shows the typical Pol 
motifs A, B and C for A family Pols at the C-terminal region and an ATP domain at 
the N-terminal region. The POLQ gene encodes a protein of 2592 amino acids (aa). 
The protein sequence shares homology to the Mus308 protein of Drosphila 
melanogaster (41, 80). Further research estimated a protein of 290 kDa, with an N-
terminal ATPase helicase domain and a C-terminal Pol domain. Despite the ATPase 
helicase domain, no helicase activity could be detected so far (80). It was shown that 
TLS Pol θ is able to bypass apurinic/apyrimidinic (AP) site and thymine glycol (Tg). 
TLS Pol θ preferentially incorporates adenine opposite the AP site and efficiently 
achieves the subsequent proceeding of the replication using the incorporated 
nucleotides as a primer (henceforth referred to as extension step) (81). Moreover, it 
can carry out the extension step from mismatches after error prone dNTP 
incorporation by human TLS Pol ι (82) or S. cerevisiae TLS Pol ζ opposite (6-4) 
photoproducts in vitro (52).The fidelity of TLS Pol θ during dNTP incorporation is 
lower than usual for A family Pols (81), since it lacks the 3’ to 5’ exonuclease 
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proofreading activity (80). It is proposed that TLS Pol θ has a function in SHM of 
immunoglobulin diversification by misincorporation over AP sites and low fidelity DNA 
synthesis (55-57). In contrast, it was suggested that human TLS Pol θ from HeLa 
cells nuclear extracts synthesizes DNA with a high fidelity and possesses 3’ to 5’ 
exonuclease proofreading activity (83).  
TLS Pol θ mutant mice show an increase of spontaneous and radiation-induced 
micronuclei suggesting a role for TLS Pol θ to maintain chromosomal stability (84, 
85) and TLS Pol θ knockout chicken DT40 B-cell line shows hypersensitivity to 
hydrogen peroxide (H2O2). Furthermore, CH12 mouse B lymphoma cells with a 
knockdown of TLS Pol θ showed elevated sensitivity to UV irradiation, mitomycin C 
(MMC), cisplatin, etoposide, Ionizing irradiation (IR) and methyl methanesulphonate 
(MMS) (86). Additionally, TLS Pol θ has been shown to have 5’ dRP lyase activity 
that is involved in short patch BER in vitro (87). 
 
4.3.1.2. TLS Pol ν 
The full length POLN gene comprises 24 exons with a length of 900 aa and is located 
on chromosome 4p16.2 that is deleted in approximately 50% of breast carcinomas 
(88). The POLN gene encodes a protein with a size of 160 kDa. The C-terminal Pol 
domain of TLS Pol ν consists of the typical A family Pol motifs A, B and C and shares 
29% identity with the C-terminus of TLS Pol θ. Neither a 3’ to 5’ nor a 5’ to 3’ 
nuclease domain were identified (45).  
In vitro experiments showed the ability of TLS Pol ν to bypass Tg (60). Interestingly, it 
has been shown that TLS Pol ν is involved in homologous recombination and cross 
link repair. Downregulation of POLN expression reduces HR and sensitizes HeLa 
cells to DSB inducing agents such as campothecin. Moreover, TLS Pol ν interacts 
with factors of the Fanconia anemia pathway that are involved in crosslink repair and 
inhibition of POLN expression sensitizes HEK293T cells to the DNA crosslinking 
agent MMC.  
TLS Pol ν interacts with the helicase HEL308 during DNA repair which shares 
homology with the POLN in the Mus308 gene of D. melanogaster (89).  
Surprisingly, DT40 POLN knockout cells are not sensitive to crosslinking agents such 
as cisplatin, MMC and the DSB inducing agent campothecin (90, 91).  
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4.3.2. Family B: TLS Polymerase zeta (ζ)  
4.3.2.1. TLS Pol ζ 
The family B includes the highly accurate DNA Pols δ (delta), ε (epsilon), α (alpha), 
and the error-prone TLS Pol ζ (92, 93). Unlike the DNA Pols δ and ε, TLS Pol ζ lacks 
the 3’ to 5’ exonuclease proofreading activity. The human TLS Pol ζ and its yeast 
homologue are heterodimeric proteins consisting of the catalytic subunit REV3 and 
the structural subunit REV7 (46, 94).  
The human REV3 protein has two transcripts that have a length of 3052 and 3130 aa 
and the larger protein has a size of 353 kDa compared to 173 kDa of the yeast 
REV3. The big differences between the yeast REV3 and the human REV3 is due to 
the exon 13 with a length of 1388 aa. Human REV3 shows ~36% identity with the N-
terminal region, ~29% identity with the central REV7 binding region and ~39% 
identity with the C-terminal DNA Pol region. The C-terminal region consists of six B-
family conserved DNA Pol motifs and two zinc finger motifs (95-97) (Fig.6). Human 
REV3 is located on chromosome 6q21 and its mouse equivalent on chromosome 10 
(98, 99). Interestingly, the location of REV3 on the chromosome 6q21 is within the 
fragile site FRA6F, which is known to be commonly deleted in several types of 
human leukemias and solid tumors (100).The human REV3 consists of an out-of-
frame ATG in the 5’ region that reduces the rate of correct transcripts. Moreover, a 
sequence upstream of the AUG initiator codon has the potential to form a stem-loop 
hairpin that lowers the rate of translation. It is suggested, that together with the 
alternative splicing form, this features of the primary and secondary structure leads to 
a low expression level of Rev3 (96, 98). Indeed, the protein concentration of REV3 in 
xenopus laevis egg extracts is much lower than those of other replication and repair 
proteins and does not change within the early embryonic development (101). Despite 
the human REV3 contains a REV7 binding region, so far, no interaction between full-
length REV3 and REV7 could be demonstrated. However, it was shown, that a 
human REV3 fragment interacts with full-length REV7 and a part of human REV7 
interacts with human REV3 and REV1 (102). Moreover, within the exon 13 of REV3, 
serine 995 was shown to be phosphorylated by CHK2 (78). Additionally, a telomere 
repeat factor homology (TRFH) docking motif site, homologies to an AT hook DNA-
binding motif containing protein1 (AHDC1) and a predicted KIA2022 protein were 
located within the exon 13 (Fig.6). 
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Fig.6 Comparison between the yeast REV3 and the human REV3 [adapted from 
(103)]. For details see text. 
 
The human TLS Pol ζ is thought to be the major error-prone TLS Pol bypassing DNA 
lesions. In contrast to viable Rev3 null yeast mutants, the disruption of Rev3 in mice 
causes embryonic lethality around midgestation (104-107). It is known that during the 
early stages of embryogenesis checkpoints are actively silenced (108) to allow rapid 
cell division and it was proposed that REV3 is essential during this strict temporal 
program. The embryonic lethal effect could not be rescued by the absence of p53 
suggesting a p53-independent pathway. However, mouse embryonic fibroblasts 
(MEFs) with a p53-deficient background could be generated (109, 110). 
An in vitro experiment showed a direct regulation of Rev3 expression level through a 
p53 responding element in the Rev3 promoter region. In addition, Rev3 expression 
was increased after DNA damage induction in a p53-dependent manner (111). An 
independent study also showed increased Rev3 mRNA level after cisplatin treatment 
(112).  
REV3 downregulation in human foreskin fibroblasts revealed decreased mutation 
frequency after treatment with UV or benzo[α]pyrene diolepoxide (113). Similarly, 
MEFs derived from mice expressing Rev3 antisense revealed decreased mutagenic 
frequency after UV treatment (114) . It was shown that Rev3 knockout in a p53-
deficient background in MEFs leads to increased chromosomal instability (109). 
Moreover, in mice with a conditional deletion of REV3, thymic lymphomas occurred 
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with decreased latency and elevated incident in a p53-deficient background (115). 
Recent in vitro and in vivo studies revealed that Rev3 inhibition increased the 
sensitivity of lymphoma to cisplatin (116). Similar, a non small cell lung cancer cell 
line (NSCLC) with downregulated REV3 transplanted in p53 deficient mice showed a 
decreased growth rate and prolonged survival upon cisplatin treatment. Additionally, 
an in vitro mutagenesis assay showed a reduced frequency of 6-thionguanine 
resistant colonies after an initial treatment with cisplatin in REV3 deficient cells 
compared to the control (116, 117). These findings assume a role of REV3 in the 
formation of resistance due to induction of mutations. 
Overexpression of REV3 in yeast led to an elevated rate of UV-induced mutagenesis 
(118). This finding together with the embryonic lethal effect after REV3 abrogation 
indicates that the level of REV3 has to be tightly regulated to maintain genomic 
integrity. 
Recent findings propose TLS Pol ζ to have a function not only in TLS synthesis but 
also in DNA repair. Rev3 disrupted DT40 chicken cells shows increased sensitivity to 
various DNA damaging agents including UV, methylmethane sulphonate (MMS), 
cisplatin and ionizing radiation (IR) (119). XPV cells treated with siRNA against TLS 
Pol ζ reveal increased UV sensitivity (120). Rev3 deletion impairs specific DNA repair 
mechanisms as homologous recombination (HR) (112) and ICL repair (121, 122). 
Furthermore, somatic hypermutation (SHM) and/or class switch recombination (CSR) 
of immunoglobulin (IgG) were affected by TLS Pol ζ ablation (33). In addition, a 
possible role of REV3 in the telomere maintenance can be suggested, due to the co-
purification of REV3 with TRF2 (123) and the presence of a predicted TRFH docking 
motif site within the exon 13 (http://elm.eu.org/). REV3 shares the AT-hook domain 
with AHDC1, which has been proposed to be phosphorylated by either ATM and ATR 
upon DNA damage, indicating a putative regulation of REV3 by ATM and ATR (124). 
It is hypothesized that REV3 could be regulated by DDR, since REV3 is 
phosphorylated by either CHK2 and ATM and ATR.  
The KIA2022 gene, which shares a conserved region with REV3, is proposed to be 
absent in patients with severe mental retardation and is highly expressed in fetal 
brain and in the adult cerebral cortex, suggesting a role in brain development and/or 
cognitive function (125). In this context, murine REV3 was first identified as a gene 
induced by treatment of primary cultured cerebral cortical cells with the seizure-
inducing agent pentylentetrazol (126). 
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The human REV7 protein has a length of 211 aa and a size of 24 kDa and shares 
~23% identity with the yeast REV7. The human REV7 is located on the human 
chromosome 1p36. Moreover, it displays ~23% identity with the spindle checkpoint 
assembly protein MAD2. Therefore, REV7 is also known as MAD2B and MAD2L2 in 
higher eukaryotes. The REV7 contains a HORMA (Hop1/Rev7/Mad2) domain that is 
known to interact with chromatin (127). Additionally, REV7 interacts with CDH1 and 
CDC20 of the anaphase-promoting complex/ cyclosome (APC/C) (128) and the 
protein MAD2, a spindle checkpoint protein (94), indicating that REV7 is involved in 
the regulation of mitosis. Interestingly, the bacterial pathogen Shigella delivers IpaB 
effectors into epithelial cells to efficiently colonize the epithelium. It has been shown 
that IpaB interacts with MAD2L and leads to cell cycle arrest (129).  
 
4.3.3. Family X: DNA Polymerase beta (β) and TLS Polymerases lambda 
(λ) and mu (µ) 
The Pols of the X family include DNA Pol β, terminal deoxynucleotidyl transferase 
(TdT), TLS Pol λ and TLS Pol µ. All the X family Pols lack the 3’ to 5’ exonuclease 
proofreading activity.  
 
4.3.3.1. DNA Pol β 
DNA Pol β is a 39 kDa monomeric protein and the encoding gene POLB is located 
on chromosome 8 in both mice and human (130). DNA Pol β consists of two 
protease resistant segments linked by a short protease sensitive segment indicating 
that DNA Pol β activity might be controlled by proteolytic activity. The 8 kDa N-
terminal lyase domain shows a strong affinity to ssDNA (131), whereas the 31 kDa 
C-terminal Pol domain specifically binds double-stranded nucleic acids (132). The 31 
kDa Pol domain consists of three subdomains. The catalytic subdomain (palm) 
coordinates two metal-ions and mediates the nucleotidyltransferase reaction (133) 
and the other subdomains mediate the binding of duplex DNA (thumb) and nascent 
base pairs (fingers) (134). It has been shown that DNA Pol β is able to fill short gaps 
in double stranded DNA (135). The 8 kDa lyase domain was shown to direct DNA Pol 
β to phosphorylated 5’ side of a DNA gap for its bypass (136) and recently to mediate 
the removal of 5’ dRP from the AP site via β-elimination after the incision step by the 
AP endonuclease (137). Beside the role of DNA Pol β in short patch BER, a function 
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in long patch BER was proposed. Both short- and long-patch repair are impaired 
after DNA Pol β ablation (138-140). Additionally, DNA Pol β has a role in bypassing 
DNA lesions such as cisplatin-DNA adducts (141). It was shown that DNA Pol β is 
not involved in the diversification of IgG (142). DNA Pol β knockout mice are not 
viable reflecting the important role of Pol β during embryonic development (143).  
NIH 3T3 mouse fibroblasts with downregulated DNA Pol β showed increased drug 
sensitivity to cisplatin and UV-induced DNA lesions, which are repaired by NER, 
suggesting a role of DNA Pol β in NER (144). Further, DNA Pol β protects MEFs 
against the cytotoxity of oxidative DNA damage (145) and the mutagenic effect of 
methylating agents such as MMS (146). Similarly, fibroblasts from DNA Pol β null 
mice were hypersensitive to the methylating agent MMS due to the missing lyase 
activity of DNA Pol β (147).  
In addition, ectopic expression of DNA Pol β leads to aneuploidy, aberrant 
localization of the centrosome-localized γ-tubulin protein during mitosis, checkpoints 
defects in vitro and tumour induction in vivo (148). Moreover, DNA Pol β is 
upregulated in chronic myelogenous leukemia (CML) patients (149). These results 
indicate that a tight regulation of DNA Pol β is essential to maintain genomic integrity. 
 
4.3.3.2. TLS Pol λ 
TLS Pol λ has a size of approximately 69 kDa and its gene POLL is located on the 
chromosome 10 in human and on the chromosome 19 in mice (42, 44). The human 
TLS Pol λ consists of 575 aa and shares 32% residue identity to Pol β consisting of 
the C-terminal Pol domain including palm, thumb and fingers and the 8 kDa 5’ dRP 
lyase domain. Additionally, TLS Pol λ contains an N-terminal BRCT (BRCA1 C-
terminus) domain followed by a serine/proline rich region that is absent in Pol β 
(150). The BRCT domain is widely found in proteins involved in DNA damage repair 
and DNA damage checkpoint control (151). TLS Pol λ shows terminal 
deoxynucleotidyl transferase activity (150), which prefers the incorporation of 
pyrimidine nucleotides (152). The TLS Pol λ has been shown to be less accurate for 
base substitutions and much less accurate for single-base deletions (153). Further, 
TLS Pol λ is unable to differentiate between matched and mismatched primer termini 
during the extension step, therefore suggesting TLS Pol λ as a candidate for NHEJ 
and as mismatch extender during TLS (153, 154). Additional in vitro studies showed 
that TLS Pol λ require their BRCT domain and is physically and functionally 
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dependent on Ku during NHEJ (155). Recently, it has been shown, that a TLS Pol λ 
variant consisting of a single nucleotide polymorphism (SNP), a cytosine/thymine 
variation, leads to increased mutation frequency, chromosomal aberration and 
defects in NHEJ (156).  
Moreover, TLS Pol λ is also discussed to participate in BER. Uracil-containing DNA 
was efficiently repaired in an in vitro reconstituted BER reaction by the 5’ dRP lyase 
activity of TLS Pol λ, in coordination with its polymerization activity (157). TLS Pol λ 
null mice are viable and fertile, but shortening of the heavy chain coding joints was 
reported (58). 
 
4.3.3.3. TLS Pol µ 
TLS Pol µ has a size of 55 kDa and its gene POLM is located on the human 
chromosome 7. It consists of 492 aa and shares 42% identity to TdT (42, 44). TLS 
Pol µ, as TLS Pol λ, contains a Pol domain and a BRTC domain. In contrast to Pol β 
and λ, the TLS Pol µ lacks a 5’ dRP lyase activity (157). Isolated TLS Pol µ is highly 
error-prone for frameshifts during DNA synthesis. Interestingly, TLS Pol µ is able to 
extend from mismatches by frameshift synthesis mechanism and thereby promoting 
microhomology search and microhomology pairing between the primer and the DNA 
template (158). Moreover, TLS Pol µ shows template-independent Pol activity under 
physiological conditions (Mg 2+ present) preferring the incorporation of pyrimidines 
and thereby generating terminal microhomology, which can be ligated by the XRCC4 
:DNA ligase IV (159) All these findings suggesting TLS Pol µ as a candidate for 
NHEJ of DSBs. It has been shown that TLS Pol µ, as TLS Pol λ, interact with the Ku-
DNA complex through its BRCT domain (155) 
Interestingly, TLS Pol u null mice are viable and fertile, but they show impaired V(D)J 
recombination due to shortening of the light chain coding ends, but not of the heavy 
chain coding ends (58, 59) 
 
4.3.4. Family Y: Rev1, TLS Polymerases eta (η), kappa (k) and iota (ι)  
The human TLS Pol members of the Y family include REV1, Pol η, Pol k and Pol ι 
[reviewed in (160)]. All the Y family members lack the 3’ to 5’ exonuclease 
proofreading activity [reviewed in (63)] and share a general conserved N-terminal Pol 
domain for the catalytic activity and a non-conserved C-terminus, which, at least for 
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the human TLS Pol ι (161) and Pol κ (162), is responsible for the regulation of the 
activity. The conserved N-terminus of the Pol domain includes five motifs (I to V) 
corresponding to the catalytic core complex of the Pol. Motif I and II form the catalytic 
epicentre (palm) with its three acidic residues harbouring the two metal ions 
mediating the nucleotide transfer. Despite sequence differences the palm domain 
with its nucleotide transfer function is widely conserved between Y-family TLS- and 
A- and B-family replicative DNA Pols. The motif III and IV belong to the finger and 
thumb domain, respectively. They bind the triphosphate of the nascent incoming 
dNTP and mediate the incorporation of the nascent nucleotide whereas the additional 
motif V binds the primer strand. The C-terminus of the motif V resides either the so 
called little finger (LF), polymerase associated domain (PAD) or the wrist that 
supports the DNA synthesis activity and is conserved and unique among the Y-family 
TLS Pols (64, 163, 164) (Fig.4). 
 
4.3.4.1. Rev1 
The 1251 aa human REV1 protein has a Mr of 138 kDa and is encoded by the gene 
REV1, located on chromosome 2. Beneath the typical Y-family conserved domains, a 
BRCT domain that binds phosphorylated proteins and thereby mediating cell cycle 
control upon DNA damage is located at the N-terminus (151). At the C-terminal end 
are two UBMs (66) followed by a TLS Pol η, Pol ι and Pol κ interaction region (165).  
It has been proposed that the nucleotide insertion activity is not the main function of 
REV1 but that REV1 helps to coordinate the Pol switch between the normal- and the 
substituting TLS Pol upon PCNA monoubiquitination. Although it was shown that 
murine REV1 binds monoubiquitinated PCNA via its UBMs, it is assumed that the Pol 
switch function of REV1 might also be dependent on the other protein interaction 
domains of REV1, e.g. the BRCT and the Pol interaction region. In detail, the C-
terminal end of human Rev1 is able to interact with several TLS Pols including Pol η, 
Pol ι, Pol κ and Pol ζ, thus supporting the assumption that Rev1 acts as a scaffold 
protein for several TLS Pols (102, 165, 166). Murine Rev1 binds ubiquitin through its 
UBMs and thereby mediating its localization to DNA damage foci. UBM mutants 
showed increased mutational aberrations after UV irradiation and elevated sensitivity 
to UV irradiation and cisplatin. This effect of sensitization was even increased in UBM 
and BRCT double-mutants (67).  
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Additionally, murine REV1 binds PCNA through its BRCT domain and the 
monoubiquitination of PCNA enhances this reaction (167). Rev1 ablation sensitizes 
DT40 chicken cells to various DNA damaging agents including cisplatin, UV 
irradiation and MMS. Additionally, Rev1 is required for the maintenance of 
chromosomal stability after UV irradiation (167). An in vivo mouse model showed that 
REV1 inhibition in B-cell lymphoma reduces cisplatin– and cyclophosphamide (CTX) 
induced mutagenesis and prolongs survival upon CTX treatments (116). 
Recently, it has been shown in vitro that Rev1 silencing impairs its replicating over G-
quadruplex (G4) structures and subsequent biased incorporation of newly 
synthesized histones due to failure to use of recycled histones, resulting in changes 
of the epigenetic pattern. It is suggested that the ablation of Rev1 and therefore the 
inaccurate recycling of histones lead to a decrease of chromatin dependent gene 
silencing (168). 
 
4.3.4.2. TLS Pol η 
Human TLS Pol η consists of 713 aa and is encoded by the POLH (Xeroderma 
pigmentosum variant, XPV) gene, localized on chromosome 6. TLS Pol η has a size 
of 78 kDa. Additional to the N-terminal conserved Pol domain, TLS Pol η consists of 
a Rev1-interacting region (RIR), an ubiquitin binding zinc finger (UBZ), a nuclear 
localization domain and a PCNA interaction peptide box (PIP). XPV cells are 
sensitive to UV irradiation and show an increased mutagenic rate despite functional 
NER indicating that TLS Pol η bypasses the UV lesions in a non-mutagenic manner 
(169). It is proposed that in the absence of TLS Pol η, TLS Pol ι serves as the error 
prone Pol which bypasses the UV induced lesions (170). Also Rev1 is suggested to 
have a regulatory role in TLS of UV induced lesions (171). TLS Pol η needs for its 
TLS activity the PIP and the UBZ domain for binding the monoubiquitinated PCNA. 
Mutation in either the PIP or the UBZ domain increases the UV sensitivity (66). 
Interestingly, it has been shown that loss of TLS Pol η in mice leads to decrease in 
adenine/thymine mutations during SHM of IgG indicating that TLS Pol η bypass 
adenine and thymine in an error prone manner (172). 
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4.3.4.3. TLS Pol κ 
The human TLS Pol κ is encoded by POLK gene and has a length of 870 aa. The 
TLS Pol κ has a size of 99 kDa and is located on chromosome 5. The N-terminal part 
consists of the conserved Pol domain whereas the variable C-terminus consists of a 
RIR, two UBZ and a PIP. It has been shown that TLS Pol κ co-localizes to a lesser 
extend with PCNA at replication foci after UV irradiation, hydroxyurea or 
benzo[α]pyrene treatment compared to TLS Pol η (173). It has been shown that ES 
cells deficient in the TLS Pol κ gene are more sensitive and acquire more mutations 
after treatment with benzo[α]pyrene and that TLS Pol κ bypasses BP-G accurately 
and efficiently in vivo (54). Additionally, XPV cells treated with siRNA against TLS Pol 
κ reveal increased UV sensitivity (120) indicating that TLS Pol κ is able to bypass UV 
induced DNA lesions. Recent findings suggest that TLS Pol κ has a function during 
NER and that its activity is dependent on RAD18 and monoubiquitinated PCNA 
(174). 
The role of TLS Pol κ in promoting tumorigenesis has been discussed since ectopic 
expression of Pol κ leads to DSBs, aneuploidy and tumorigenesis in nude mice (71). 
 
4.3.4.4. TLS Pol ι 
Human TLS Pol ι is encoded by the POLI gene consists of 715 aa. The TLS Pol ι has 
a size of 80 kDa and is localized on chromosome 18. TLS Pol ι shares with the other 
Y family members the N terminal conserved Pol domain and at the variable C-
terminal a RIR, two UBMs and the PIP. In contrast to TLS Pol η and Pol κ the PIP of 
TLS Pol ι is located in the middle of the protein between the conserved Pol domain 
and the Rev1 binding domain. Interestingly, TLS Pol ι possess a 5’ dRP lyase activity 
(175) that is located within a nuclear localization domain (176).  
As in the case of TLS Pol η, the PIP and the UBM domains of TLS Pol ι are important 
for localization to the replication fork by binding monoubiquitinated PCNA (66). The 
localization and accumulation of TLS Pol ι to stalled replication forks is widely 
dependent on TLS Pol η through physical interaction (177). Recently, it has been 
shown that human fibroblasts in which TLS Pol ι is stably downregulated exhibits 
increased sensitivity against H2O2 and menadione and BER is decreased (176). 
Additionally, after H2O2 treatment, TLS Pol ι binds to chromatin and interacts with the 
BER factor XRCC1, suggesting TLS Pol ι as repair Pol of oxidative damage (176).  
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4.4. Translesion synthesis 
4.4.1. One- and two-Polymerase mechanism 
There are TLS Pols that are able to replicate over a DNA lesion by both incorporating 
nucleotides opposite the damaged DNA and by extending from the inserted 
nucleotides. The so called one-Pol mechanism has been shown to be performed by 
TLS Pol κ replicating over AP sites in vitro and by TLS Pol η bypassing UV induced 
CPDs in vivo (Fig.7). 
 
Incorporation Extension
 
Fig.7 One Pol error-free bypass of a TT-CPD carried out by TLS Pol η [adapted from 
ref. (178)]. For details see text. 
 
However, other lesions such as BP-G or cisplatin-DNA adducts can not be replicated 
by a one-Pol mechanism but requires a continuous progression of two Pols, a so 
called two-Pol mechanism. The first Pol incorporates the nucleotides opposite the 
DNA lesion and a second Pol subsequently extends from the inserted nucleotides. 
Depending on the type of DNA lesion, different pairs of Pols interact together to 
replicate the DNA lesion resulting in either an error-free or error-prone bypass 
(Fig.8).  
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Incorporation Extension
 
Fig.8 Two-Pol mechanism for bypassing a BP-G or cisplatin-DNA adducts. The first 
step is achieved by a TLS Pol incorporating a nucleotide in an error-free or error-
prone manner subsequently followed by TLS Pol ζ carrying out the extension step 
[adapted from ref. (178). For details see text. 
 
4.4.2. Apurinic/ apyrimidinic (AP) sites 
AP sites present a strong block to continued synthesis by the replicative DNA 
machinery, Pol β is the primary enzyme used for gap filling DNA synthesis, during 
BER. However, if AP sites are not repaired, a one-Pol mechanism has been 
proposed in an in vitro assay where the TLS Pol θ preferentially incorporates an 
adenine opposite the AP site followed by a guanine and cytosine/thymine (81). In 
addition, it has been shown in vitro that TLS Pol η is able to incorporate nucleotides 
opposite AP sites preferentially adenine and guanine and extend from the 
incorporated nucleotide favouring an adenine (179). An adenine opposite the AP site 
is also the best primer for the extension step of TLS Pol θ (81).  
In vitro studies showed that isolated TLS Pol λ from calf thymus is able to replicate a 
damaged (apurinic) DNA template in vitro (180). Similarly, isolated human TLS Pol λ 
is able to synthesize over an AP site and this bypass is stimulated by PCNA in vitro 
(181) 
Alternatively, AP sites might also be bypassed by a two-Pol mechanism. It has been 
suggested that TLS Pol µ is capable to incorporate nucleotides opposite AP sites in 
vitro although in this process deletions are frequently generated due to primer 
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realignment (182). Similary, TLS Pol ι and REV1 are able to incorporate one 
nucleotide opposite an AP site (183). 
Thus, AP sites might also by bypassed by a two-Pol mechanism, with TLS Pol µ, TLS 
Pol ι or REV1 performing the insertion step followed by second Pol carrying out the 
extension step.  
 
4.4.3. 7, 8-dihydro-8-oxoguanine (8-oxo-G) 
8-oxo-G is generated by oxidative stress and leads to frequent misincorporation (10-
75%) of adenine opposite the 8-oxo-G, thus, generating a guanine:cytosine to 
thymine:adenine transversion. It has been shown that 8-oxo-G lesion in vitro can be 
bypassed by TLS Pol µ resulting in a -1 deletion due to primer realignment during 
TLS (182). More recently, it has been shown that 8-oxo-G lesion in vitro are mainly 
bypassed by TLS Pol λ and TLS Pol η and that the presence of PCNA and RP-A 
increases the fidelity of correct cytosine incorporation over the incorrect adenine 
incorporation opposite the 8-oxo-G by a factor of 1200 fold for TLS Pol λ and by a 
factor of 68 fold for TLS Pol η (184). 
 
4.4.4. Thymine glycol (Tg) 
Tg is the most common thymine lesion induced by reactive oxygen species (ROS) 
(185). In vitro studies have shown, that TLS Pol θ is able to incorporate nucleotides 
over both 5R- and 5S-diastereoisomers of Tg with similar efficiency but fails to 
process the extension step (81). Similary, the TLS Pol ν is able to bypass 5S-Tg in 
an error-free manner whereas the bypass of 5R-Tg was less acurate (60).The TLS 
Pol λ has been shown to bypass a Tg in gapped DNA structures. Additionally, 
dependent on the size of the gap, TLS Pol λ is able to possess the extension step. 
The bypass fidelity of TLS Pol λ is thereby increased by the presence of PCNA (186). 
Recently, a two-Pol mechanism in vivo for error-free Tg bypass including TLS Pol κ 
as nucleotide inserter and TLS Pol ζ as extender was proposed (187). 
 
4.4.5. (6-4) photoproduct 
The major DNA lesion induced by UV irradiation is the (6-4) photoproduct that leads 
to a 44° bend of the DNA helix and inhibits the DNA synthesis (188, 189). Beside the 
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common repair of (6-4) photoproduct by NER, in vitro experiments have shown that 
TLS Pol µ is able to bypass the (6-4) photoproduct (182). Two alternative two-Pol 
mechanism models to bypass the (6-4) photoproduct have been proposed using an 
in vivo plasmid based model. In the first model TLS Pol ι and TLS Pol η alternatively 
incorporate nucleotides at the 3’ thymine or 3’ cytosine in an error-free or error-prone 
manner, subsequently extended by a yet unknown DNA Pol. In the second model a 
yet unknown Pol incorporates nucleotides at the 3’ thymine or 3’ cytosine in an error-
free manner. Subsequent extension is carried out by TLS Pol ζ (190).  
 
4.4.6. Cyclobutane pyrimidine dimer (CPD) 
CPDs are DNA lesions generated by UV irradiation and are associated with the 
hereditary disease XPV due to a lack of TLS Pol η (169). CPDs are replicated in vitro 
by both the one- and the two-Pol mechanism. In vitro experiments revealed that TLS 
Pol µ can bypass a CPD in a mainly error-free manner (182). Further, TLS Pol η is 
able to replicate efficiently over CPD in vitro thereby bypasses the CPD with lower 
fidelity and higher error rates at the 3’ thymine than at the 5’ thymine. Additionally, 
the UV irradiation induced mutagenesis is higher at the 3’ base (191). Recently, it 
has been shown in vivo that TLS was reduced and mutagenicity increased in cells 
lacking TLS Pol η using a quantitative TLS assay system measuring TLS across 
CPDs. Most of the mutations could be found opposite the 3’ thymine of the CPD. 
Similar to the in vitro studies, the error frequency of TLS Pol η in vivo is 
approximately 1% (192). 
TLS across CPD can also be processed by the two-Pol mechanism model. Very 
recently it has been proposed in an in vivo model that CPD in XPV cells, e.g. in the 
absence of TLS Pol η, is replicated by the two-Pol mechanism in an error-prone 
manner. The two step model includes either TLS Pol ι, TLS Pol κ or a yet undefined 
Pol or a combined action for the first and the second pyrimidine nucleotide 
incorporation opposite a CPD, followed by the extension step achieved by TLS Pol ζ 
(120). 
4.4.7. Benzo[α]pyrene-guanine (BP-G) 
BP-G is a major tobacco smoke-induced DNA lesion which is associated with the 
development of lung cancer (8). In vitro and in vivo studies showed efficient bypass 
of BP-G by TLS Pol κ using a gapped plasmid consisting of a BP-G lesion (193).  
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Additionally, BP-G has been shown to be bypassed by a two-Pol mechanism in vivo. 
The accurate incorporation of the nucleotides is carried out either by TLS Pol η or 
TLS Pol κ followed by the extension of TLS Pol ζ (194). 
 
4.4.8. Intrastrand-crosslinks 
Cross-linking agents including cisplatin, which induces DNA intra- and interstrand 
crosslinks (ICLs) are widely used in anticancer chemotherapy. Intrastrand-crosslinks 
are the most prevalent form of cisplatin-induced DNA adducts (>90%) (7) and are 
bypassed by the one- or the two-Pol mechanism. In vitro experiments revealed that 
Pol β can bypass a d(GpG)-cisplatin intrastrand adduct (141). Additionally, it has 
been reported that TLS Pol η in vitro is able to bypass a d(GpG)-cisplatin intrastrand 
adduct thereby preferentially incorporates a cytosine over the d(GpG)-cisplatin 
intrastrand adduct (179). Recently, it has been shown in vivo, that either TLS Pol κ or 
TLS Pol η incorporate the correct nucleotide opposite the d(GpG)-cisplatin 
intrastrand adduct and TLS Pol ζ carries out the extension step (194). Similarly, in 
vivo experiments proposed a model where RAD18/RAD6 dependent 
monoubiquitination of PCNA activates the bypass of the d(GpG)-cisplatin intrastrand 
adduct by TLS Pol η and where activated TLS Pol ζ performs the subsequent 
extension in a Rev1-dependent manner (122). 
 
4.4.9. Interstrand-crosslink (ICL) 
Beside the major intrastrand-crosslinks, cisplatin only forms less than 10% ICLs (7).  
It has been found using a plasmid-based recombination assay, that the repair of ICLs 
in the recombination-dependent repair involves components of mismatch repair, 
ERCC1-XPF, REV3, Fanconia anemia proteins and homologous recombination 
(121). Other findings revealed that ICL are also repaired in a recombination-
independent pathway including both NER and TLS Pol ζ and Rev1 (195). 
 
In summary, TLS Pols are involved in tolerating a broad range of DNA damages 
highlighting the importance of TLS in the maintenance of genomic integrity. 
It has been shown that a controlled regulation of the TLS Pols is essential to bypass 
DNA lesions and to sustain DNA replication. However, a stringent regulation of the 
TLS Pols is indispensable to avoid the accumulation of mutations.  
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In combination with the DNA repair mechanisms, the TLS Pols build a powerful 
mechanism to maintain genomic integrity. 
 
4.5. Relevance of TLS Polymerases in cancer therapy 
As reviewed by Lange et al. (65), the TLS Pol are discussed to have an emerging 
role as targets in cancer therapy, since TLS Pol are involved in both DNA damage 
repair and tolerance mechanisms. 
The TLS Pols contribute to mutagenesis due to the incorporation of incorrect 
nucleotides opposite DNA lesions. Since the accumulation of mutations can give rise 
to carcinogenesis and development of resistance, the inhibition of TLS Pols was 
proposed as a cancer treatment strategy, which should sensitize cancer cells to DNA 
damaging agents and at the same time reduce damage-induced mutagenesis (196). 
To date, no specific inhibitors for Y family TLS Pols are available except for the 
pyrene nucleotide analogs OXT-GTP and OX-ATP, which are able to inhibit TLS Pol 
η (197). Additionally, some natural inhibitors are known to have inhibitory effects 
such as Petasiphenol, which is a specific inhibitor of TLS Pol λ in vitro [(198, 199)]. It 
has been shown that Petasiphenol has antiangiogenic activity [(200) and reviewed in 
(198)]. Tormetic acid is another inhibitor of TLS Pol λ and β but also of the replicative 
DNA Pols such as Pol α. Tormetic acid showed an antitumorigenic activity in vivo 
[reviewed in (198)]. 
Another study has shown that gene expression of TLS Pol θ is upregulated in two 
cohorts of patients with untreated primary breast cancers. Interestingly, the 
upregulation of gene expression of TLS Pol θ correlated with poor clinical outcome. 
Therefore, inhibition of the expression/activity of TLS Pol θ may improve the clinical 
outcome and increase responsiveness to genotoxic treatments (201). 
The concept of “synthetic lethality” describes another therapeutical approach where 
defects in two pathways alone can be tolerated but become lethal when combined. 
This concept has been extended by the idea of “synthetic sickness”, whereas the 
combined loss/mutation of function of two genes does not kill cells but significantly 
impairs cellular fitness (Fig.9).  
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Gene A Gene B
++ viable
+ - viable
+- viable
- - lethal/Impaired fitness
 
Fig.9 The Concept of synthetic lethality/sickness explains that a cell can compensate 
either the loss of gene A or B but the loss of both genes leads either to lethality or 
impaired fitness. For details see text. 
 
DDR is often abrogated in cancer cells and it was proposed to develop cancer 
treatments taking advantage of cancer-specific DDR alterations (28). 
The principle of synthetic lethality was successfully applied in cancer therapy of 
patients carrying mutations in BRCA1 or BRCA2, a specific DNA-repair defect. 
Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) resulted 
in synergistic antitumor activity in the treatment of hereditary ovarian- and breast 
cancer of patients with BRCA mutation (202). 
Experiments with yeast deficient in mismatch repair proteins revealed a synthetic 
lethal effect when either yeast Pol 3 (human ortholog Pol δ) (203) or yeast Pol 2 
(human ortholog Pol ε) (204) was inhibited. The overlapping functions of mismatch 
repair and DNA Pol proofreading activity are conserved from yeast to humans, which 
indicate that inhibition of specific Pols might selectively kill mammalian tumors 
deficient in mismatch repair.  
Indeed, it was recently shown that inhibition of Pol β or γ induces synthetic 
sickness/lethality in MSH2-respectively MLH1-deficient human cancer cells (205). 
Moreover, the inhibition of Rev3, the catalytic subunit of TLS Pol ζ, has been shown 
to sensitize in vitro human fibroblasts to cisplatin and decreases the formation of 
cisplatin resistant cells (112). Recent findings showed that suppression of Rev3 
increases the sensitivity of chemoresistant lung tumors to cisplatin in an in vivo 
mouse xenograft model (117). 
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As will be documented in chapter 7, inhibition of the TLS Pol ζ per se confers 
synthetic sickness/lethality specifically in a variety of different cancer cells whereas 
normal cells are less affected, thus identifying REV3 as a potential target for cancer-
specific therapy. 
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6. Aim of the thesis 
Rev3 is the catalytic subunit of the DNA TLS Pol ζ. It was shown before that inhibition 
of Rev3 increases the sensitivity of yeast and human normal cells to a variety of DNA 
damaging agents and reduces the formation of resistant cells. The initial aim of the 
thesis was to investigate how REV3 inhibition affects sensitivity and resistance 
formation of cancer cells after cisplatin treatment. Surprisingly, it was found that 
inhibition of REV3 expression per se suppresses colony formation of a mesothelioma 
cancer cell line. This finding was subsequently further investigated.  
First, the reduction of colony formation after REV3 inhibition was tested for its 
specificity of cancer cell lines. As a second aim, it was tried to elucidate why colony 
formation was reduced in cancer cells after REV3 inhibition e.g. induction of 
apoptosis, senescence or quiescence. The third aim was to address which molecular 
alteration, e.g. DNA damage accumulation, triggers the reduction in colony formation. 
The final aim was to identify, which molecular pathway, e.g. DDR, was activated after 
REV3 inhibition and how the activation of this pathway resulted in the observed 
reduction of cancer cell growth. 
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7.1. Abstract 
Rev3 is the catalytic subunit of DNA translesion synthesis polymerase zeta (TLS Pol 
ζ). Inhibition of Rev3 increases the sensitivity of human cells to a variety of DNA 
damaging agents and reduces the formation of resistant cells. Surprisingly, it was 
found that silencing of REV3 per se suppresses colony formation of lung (A549, 
Calu-3), breast (MCF-7, MDA-MB231), mesothelioma (IL45 and ZL55) and colon 
(HCT116 +/-p53) tumor cell lines whereas normal cell lines (AD293, LP9-hTERT) and 
the normal mesothelial primary culture (SDM104) are less affected. Inhibition of 
REV3 expression in cancer cells leads to an accumulation of persistent DNA damage 
as indicated by an increase in phospho-ATM-, 53BP1- and phospho-H2AX-foci 
formation, subsequently leading to the activation of the ATM-dependent DNA 
damage response cascade. REV3 inhibition in p53-proficient cancer cell lines results 
in a G1-arrest and induction of senescence as indicated by the accumulation of p21 
and an increase in senescence-associated (SA)-β-Galactosidase activity. In contrast, 
REV3 inhibition in p53-deficient cells results in growth inhibition and a G2/M-arrest. A 
small fraction of the p53-deficient cancer cells can overcome the G2/M-arrest, which 
results in mitotic slippage and aneuploidy.  
These findings reveal that REV3 inhibition per se suppresses cancer cell growth 
whereas normal cells are less affected, thus identifying REV3 as a potential target for 
a cancer-specific therapy. 
 
7.2. Introduction 
Screening in Saccharomyces cerevisiae for mutants defective in UV-induced 
mutagenesis revealed the so called “reversionless” phenotype (REV), which is 
characterized by a diminished frequency of mutations reverting a specific marker-
gene deficiency (1). Two genes that confer this phenotype when absent are Rev3 
and Rev7, the catalytic and the structural subunit of the DNA TLS Pol ζ, respectively 
[2-3]. The mammalian REV3L gene (hereafter REV3) encodes a ~350 kDa protein 
(REV3) consisting of a large C-terminal DNA Pol subunit, which misses the 
characteristic proofreading activity present in other B-family DNA Pols (reviewed in 
(2)). REV3 interacts via a specific binding domain with REV7 but no additional 
protein-protein interaction sites were identified. Deletion of REV3 is embryonic lethal 
around midgestation (3-6) whereas over-expression of REV3 leads to increased 
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spontaneous mutation rates (7) confirming that REV3 expression has to be tightly 
regulated to maintain genomic integrity. Conversely, one study found that REV3 
expression was down-regulated in colon carcinomas compared to adjacent normal 
tissue (8) whereas another study found that REV3 expression was elevated in human 
gliomas tissues resected before therapy compared to normal brain tissues (9).  
Pol ζ belongs to the functional group of TLS DNA Pols, which are characterized by a 
less stringent active site and a lower processivity compared to the high fidelity 
replicative DNA Pols (reviewed in (2)). TLS Pols contribute to the maintenance of the 
genomic integrity by allowing DNA replication to continue in the presence of DNA 
adducts, which otherwise could lead to DNA replication fork break-down and 
subsequent chromosomal instability. TLS Pol ζ is the major extender from 
mismatches formed when incorrect nucleotides are inserted opposite DNA adducts 
thereby contributing to mutation formation on the nucleotide level. The unique 
function of REV3 is highlighted by the fact that the suppression of REV3 increases 
sensitivity and decreases mutagenesis induced by UV light, cisplatin and other 
mutagens in human and mouse fibroblasts (10-12). 
Although disruption of mouse REV3 leads to embryonic lethality, it is possible to 
generate REV3-deleted mouse embryonic fibroblasts (MEFs) in a p53-deficient 
background (13). Spontaneous chromosomal instability was observed in REV3-
deleted MEFs and REV3-deleted cell lines (14-16) confirming the involvement of 
REV3 in suppression of chromosomal instability. Recently, it was shown that REV3 is 
involved not only in DNA damage tolerance, but also in DNA repair mechanisms, e.g. 
interstrand crosslink repair (17), homologous recombination (11) and non-
homologous end joining as indicated by the deficiency of REV3-deleted B cells in 
somatic hypermutation of immunoglobulin genes (16).  
DNA damage induction results in the activation of an evolutionary conserved signal 
cascade known as DNA damage response (DDR) (reviewed in (18)). Induction of 
DNA double strand breaks (DSBs) results in recruitment and activation of ataxia-
telangiectasia mutated (ATM). Activated ATM phosphorylates the histone variant 
H2AX at serine 139 (γH2AX) near DNA DSBs, subsequently leading to an 
accumulation of DDR proteins at DNA double strand breaks, which can be visualized 
by immunofluorescence microscopy as distinct foci. Once ATM activation reaches a 
certain threshold, checkpoint kinase CHK2 is phosphorylated resulting in the 
accumulation of p53, leading to the accumulation of the cyclin-dependent kinase 
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inhibitor p21. Prolonged activation of p21 after DNA damage is associated with a 
terminal proliferation arrest, e.g. senescence. 
While investigating how inhibition of REV3 expression affects cisplatin-induced 
mutagenesis it was observed that inhibition of REV3 expression per se reduces 
cancer cell growth whereas growth of normal cells is less affected. Inhibition of REV3 
expression in cancer cells leads to the accumulation of persistent DNA damage 
independently of the p53-status. In p53-proficient cancer cells, inhibition of REV3 
expression results in the activation of the ATM-dependent DDR cascade leading to 
senescence induction. In p53-deficient cancer cells, inhibition of REV3 expression 
results in a G2/M-arrest and increases the fraction of aneuploid cells. In contrast, 
inhibition of REV3 expression in normal cells neither reduces colony formation nor 
activates the DDR cascade. It is shown for the first time that depletion of a TLS Pol 
confers synthetic sickness/lethality specifically in cancer cells.  
 
7.3. Material and Methods 
Cell Lines and Culture 
All cell lines used in this study were authenticated by DNA fingerprinting (Microsynth, 
Switzerland). SDM104 was maintained as described previously (19). All other cell 
lines were maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) high glucose 
(Sigma) supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 10% fetal calf 
serum (FCS) and 1% (w/v) penicillin/streptomycin. All cells were grown at 37°C in a 
humidified atmosphere containing 5% CO2. Additional details can be found in 
Supplemental Materials and Methods. 
Vector Production and Transduction 
Replication-deficient lentiviral particles were produced, titrated and used for 
transduction as described previously (20, 21). Additional details can be found in 
Supplemental Materials and Methods. 
Plasmid Transfection 
Cells were transfected using LipofectamineTM 2000 (Invitrogen) according to the 
manufacturer’s instructions with pSuperior.puro containing either shSCR or three 
distinct shRNA sequences targeting the REV3 mRNA. Additional details can be 
found in Supplemental Materials and Methods. 
Colony Formation Assay 
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Crystal violet staining was performed after colonies were visible by eye and the 
number of colonies was determined by eye applying the same threshold for colony 
size to all transduced cell lines. The number of colonies obtained by mock treatment 
was set to 100%. 
Quantitative Real-Time PCR 
RNA from samples was isolated using RNeasy Mini kit (Qiagen) and reverse 
transcription was performed on 300 ng RNA (Qiagen QuantiTect® Reverse 
Transcription protocol). The quantitative expression of REV3 mRNA was measured 
by SYBR-Green PCR assay (Applied Biosystems) on a Prism 5700 detection system 
(SDS, ABI/Perkin/Elmer). Additional details can be found in Supplemental Materials 
and Methods. 
Immunofluorescence Microscopy 
Immunofluorescence microscopy was essentially performed as described (22). 
Details can be found in Supplemental Materials and Methods. 
Flow Cytometry 
Detection of BrdU incorporation in DNA synthesizing cells was carried out using the 
anti-BrdU antibody (BD Biosciences #555627) according to the manufacturer’s 
instructions. Additional details can be found in Supplemental Materials and Methods. 
Senescence Associated (SA) Βeta-galactosidase Assay 
The expression of SA--galactosidase was determined by SA--galactosidase 
staining as described (23). 
Western analysis 
Protein extracts (30μg) were separated by 4-12% SDS–PAGE and transferred onto 
PVDF membranes. Immunoblotting was performed as described (24). Details can be 
found in Supplemental Materials and Methods. 
ELISA 
Cells were washed three times with PBS and serum-free DMEM was added for 24 
hours. Conditioned media were filtered and cell number was determined in every 
experiment by hemocytometer. ELISA was performed using human IL-6 Quantikine 
ELISA Kit (R&D systems #D6050). The data were normalized to the cell number and 
reported as pg/ml. 
Statistical analysis 
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P-values were calculated using the two-tailed Student's t test, were * represents p 
values <0.05 and ** represents p values <0.01. Error bars represent standard error of 
the mean. 
 
7.4. Results 
Inhibition of REV3 expression per se suppresses colony formation of cancer cells 
To study the effect of inhibition of REV3 expression on cisplatin-induced 
mutagenesis, we established a lentiviral-based system, which allowed us to 
significantly inhibit REV3 expression in all cell lines and the primary culture used in 
this study (Figure S1A and S1B). Inhibition of REV3 expression did not significantly 
reduce colony formation of the normal cell line AD293 (99% remaining colonies 
compared to mock treated control), the primary mesothelial culture SDM104 (81%), 
and the hTERT-immortalized derivative of the mesothelial primary culture LP9 (LP9-
hTERT) (98%) (Figure 1A and S2A). Surprisingly, inhibition ofREV3 expression per 
se significantly suppressed colony formation of the p53-proficient adenocarcinoma 
cell line A549 (30%), the p53-deficient adenocarcinoma cell line Calu-3 (57%), the 
p53-deficient breast cancer cell line MDA-MB231 (47%), the p53-proficient breast 
cancer cell line MCF-7 (32%), the human mesothelioma cell line ZL55 (27%) and the 
rat mesothelioma cell line IL45 (4%) compared to mock treated control (Figure 1A 
and S2A). 
In the isogenic p53-proficient and -deficient HCT116 colorectal carcinoma cell lines, 
there was no significant difference in the reduction of REV3 expression levels after 
transduction with an MOI of 170, as used for the cell lines described above, or a MOI 
of 800 (Figure S1B). However, only the high-titer transduction significantly 
suppressed colony formation of p53-proficient (49%) and -deficient HCT116 (54%) 
compared to mock control (Figure 1B and S2B). Inhibition of REV3 expression by 
high-titer transduction did not significantly reduce colony formation of the normal cell 
line AD293 (74%) compared to mock control (Figure 1B and S2B).  
Inhibition of REV3 expression by transduction with three plasmids, one encoding the 
same siRNA as the lentiviral-based particles plus two plasmids encoding siRNAs 
targeting alternative sites of the REV3 mRNA (named REV3-5 and REV3-6) 
significantly reduced colony formation in the mesothelioma cell line IL45, whereas the 
normal cell line AD293 was not affected (Figure S3). Therefore, we conclude that the 
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observed reduction in colony formation is due to inhibition of REV3 expression and 
not due to an unspecific off-target effect of the REV3-4 siRNA. Thus, inhibition of 
REV3 expression per se significantly suppresses colony formation in cancer cell lines 
whereas colony formation of normal cells is less affected.  
Cancer cells accumulate persistent DNA double strand breaks after inhibition of 
REV3 expression 
53BP1- and γH2AX foci formation is regarded as a maker for DNA double strand 
breaks (22) and a recent study showed that their numbers where increased after 
persistent DNA damage induction (25). 7 days after transduction, inhibition of REV3 
expression in A549 cells increased the average number of P-ATM and γH2AX foci 
per cell by a factor of 3.8 and 2.3, respectively, compared to the mock control (Figure 
2A). Inhibition of REV3 expression increased the fraction of A549 cells containing 
more than two 53BP1 foci to 34% compared to mock (2%) and scrambled (16%) 
control (Figure 2A). P-ATM foci formation was also elevated in both p53-proficient 
and -deficient HCT116 cells after inhibition of REV3 expression by a factor of 2.3 and 
2.5, respectively, compared to the scrambled control (Figure 2B). In contrast, 
inhibition of REV3 expression in the normal cell line AD293 did not significantly 
increase P-ATM, 53BP1- or yH2AX-foci formation compared to the scrambled control 
(Figure 2A).  
DNA double strand breaks, which are not repaired either due to complex DNA 
modifications or deficiencies in molecular mechanisms result in the formation of 
persistent DNA double strand breaks (reviewed in (18)). P-ATM foci at persistent 
DNA double strand breaks are significantly larger in size than the initial foci 
detectable immediately after damage initiation (26). Microscopic analysis revealed 
that the DDR foci induced in REV3-depleted cells 7 days after transduction were 
larger in size compared to the background DDR-foci present in the mock controls 
(Figure 2A). 
Chromosomal instability indicated by an elevated number of micronuclei were 
observed in MEFs with REV3 deletion (13). Similarly, the number of micronuclei 
increased in A549 cells by a factor of 9 after inhibition of REV3 expression compared 
to mock control (Figure 2C). Micronuclei formation was not significantly elevated after 
inhibition of REV3 expression in AD293 cells (Figure 2C). Thus, inhibition of REV3 
expression induces the formation of persistent DNA double strand breaks and 
accumulation of chromosomal instability in cancer cells whereas normal cells are less 
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affected. In addition, our results indicate that persistent DDR-foci formation after 
inhibition of REV3 expression is not dependent on p53. 
Inhibition of REV3 expression suppresses proliferation of cancer cells 
Since persistent DNA adducts block DNA replication and activate the DDR pathway 
we investigated whether inhibition of REV3 expression results in reduced cellular 
proliferation. Quantitative analysis of BrdU incorporation revealed that cellular 
proliferation of A549 cells was reduced by inhibition of REV3 expression to 21% 
compared to 37% and 38% in mock and scrambled control, respectively (Figure 3, 
see also figure 2A). Inhibition of REV3 expression reduced proliferation of p53-
proficient HCT116 cells to 25% and in p53-deficient HCT116 cells to a lesser extend 
to 33%, compared to 41% and 45% in their corresponding scrambled control, 
respectively (Figure 3). In contrast, the percentage of replicating cells in the normal 
cell line AD293 and the primary cell culture SDM104 was not diminished by inhibition 
of REV3 expression (Figure 3). Thus, inhibition of REV3 expression suppresses 
cellular proliferation of cancer cells whereas proliferation of normal cells is not 
affected. 
Inhibition of REV3 expression activates the DNA damage response pathway in 
cancer cells 
We investigated whether the observed accumulation of persistent DNA double strand 
breaks in cancer cells results in the activation of the canonical ATM-kinase mediated 
DNA damage response pathway, which is induced by DNA double strand breaks 
(reviewed in (18)). As described above, the number of phospho-ATM foci per cell 
increased after inhibition of REV3 expression compared to mock and scrambled 
control in A549, p53-proficient and -deficient HCT116 cells whereas no significant 
increase occurred in AD293 normal cells (Figure 2A and 2B). In A549 cells, inhibition 
of REV3 expression resulted in increased phosphorylation of the checkpoint kinase 
Chk2 (P-Chk2) and the accumulation of p53 and the senescence mediator p21 
(Figure 4A). In p53-proficient HCT116 cancer cells, inhibition of REV3 expression 
also resulted in an accumulation of p21, which was absent in the p53-deficient 
isogenic cell line (Figure 4A). Thus, in p53-proficient cancer cells, inhibition of REV3 
expression results in the activation of the canonical ATM-dependent DDR pathway. 
 
 
Inhibition of REV3 expression induces a G1-arrest in p53-proficient cancer cells 
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We tested whether the activation of the DDR pathway and the reduction in BrdU 
incorporation due to inhibition of REV3 expression change the cell cycle distribution 
of cancer cells. Depletion of the S-phase after inhibition of REV3 expression, as 
mentioned above, was accompanied by a significant increase in the fraction of A549 
cells in the G1-phase of the cell cycle to 62% compared to 53% and 51% in the mock 
and scrambled control, respectively (Figure 3). Similarly, the fraction of p53-proficient 
HCT116 cells in the G1-phase increased to 38% after inhibition of REV3 expression 
compared to 26% in scrambled control, respectively (Figure 3). In the normal cell line 
AD293 and the primary cell culture SDM104, neither the fraction of cells in S-phase 
was decreased nor was the fraction of cells in G1-phase increased after inhibition of 
REV3 expression compared to mock and scrambled control (Figure 3). A small but 
significant increase in the fraction of cells in the G2-phase was observed in p53-
proficient HCT116 cells after inhibition of REV3 expression (23%) compared to mock 
(17%) and scrambled control (19%). In addition, protein levels of cyclin E, which 
accumulates during the G1-phase and is required for the transition from G1 to S-
phase, increased after inhibition of REV3 expression in p53-proficient- but not in p53-
deficient HCT116 cancer cells (Figure 4A). Thus, inhibition of REV3 expression in 
p53-proficient cancer cell lines induces a G1-arrest, respectively S-phase depletion, 
whereas the cell cycle distribution of normal cells is not affected.  
Inhibition of REV3 expression induces senescence in p53-proficient cancer cells 
Although inhibition of REV3 expression slightly increased the fraction of Sub-G1cells 
in p53-proficient A549 and HCT116 cells, no significant induction of apoptosis as 
indicated by an increased fraction of Sub-G1 cells (Figure 3) or PARP cleavage 
(Figure 4A) was observed in the remaining normal- and cancer cell lines tested in this 
study.  
Since senescence can be induced by persistent DNA damage (25), we investigated 
whether cells are senescent after inhibition of REV3 expression. Induction of 
senescence can not be identified by a single marker but is associated with a variety 
of distinct cellular and molecular changes (reviewed in (27)). Microscopic analysis 
after crystal violet staining revealed that the morphology of normal AD293 cells was 
not changed 7 days after inhibition of REV3 expression compared to mock and 
scrambled control (Figure S4). In the p53-proficient cancer cell lines included in this 
study, the majority of the colonies were smaller in size after inhibition of REV3 
expression and the cells of these colonies displayed morphological changes which 
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are associated with senescence, e.g. increased cell size and flattened shape, 
whereas cell morphology was not affected in mock and scrambled control (Figure 
S4). SA-β-Galactosidase staining revealed increased SA-β-Galactosidase activity in 
IL45, A549- and HCT116 p53-proficient cells after inhibition of REV3 expression 
(Figure S4 and Table 1). No increase in SA-β-Galactosidase staining after inhibition 
of REV3 expression was detectable in the normal cells AD293 or in the p53-deficient 
MDA-MB231 and HCT116 cancer cell lines. As mentioned above, G1-arrest, 
respectively S-phase depletion and p21 accumulation were observed in A549 and 
p53-proficient HCT116 cells after inhibition of REV3 expression (Figure 3 and 4A).  
An increase in persistent DNA damage indicated by residual 53BP1/γH2AX foci is 
associated in human foreskin fibroblasts with a senescence-associated secretory 
phenotype including cytokine secretion such as IL-6 (25). 12 days after transduction, 
IL-6 secretion was increased in A549 cell after inhibition of REV3 expression 
compared to mock and scrambled control (Figure 4B). In contrast, inhibition of REV3 
expression in p53-deficient HCT116 cells did not result in a G1-accumulation nor did 
it increase p21 levels or increase SA-β-Galactosidase staining (Figure 3, 4A, S4 and 
Table 1). Similarly, G1-accumulation and SA-β-Galactosidase staining were 
abolished in A549 by p53 inhibition (Figure 3 and Table 1). Thus, inhibition of REV3 
expression per se induces senescence in p53-proficient cancer cells only. 
Inhibition of REV3 expression induces a G2/M arrest and aneuploidy in p53-deficient 
cancer cells 
No G1-arrest was detectable in p53-deficient HCT116 cell after inhibition of REV3 
expression (Figure 3). Instead, inhibition of REV3 expression in the p53-deficient 
HCT116 cell line significantly increased the fraction of cells in the G2/M-phase to 26% 
compared to 17% and 18% in the mock and scrambled control, respectively (Figure 
3). In addition, inhibition of REV3 expression also increased the fraction of aneuploid 
cells which did not incorporate BrdU (AN, aneuploid non-dividing) to 7% compared to 
3% and 4% in the mock and scrambled control (Figure 3). The fraction of aneuploid 
cells, which were still incorporating BrdU (AD, aneuploid dividing) was not increased 
after inhibition of REV3 expression in p53-deficient HCT116 cells compared to mock 
and scrambled control (Figure 3). Thus, inhibition of REV3 expression in p53-
deficient cancer results in an accumulation of G2/M-arrested- and non-dividing 
aneuploid cells.  
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In an effort to provide proof-of-principle, we inhibited p53 expression in p53-proficient 
A549 cancer cells (Figure S1C). Inhibition of p53 expression in A549 cells resulted in 
a significant increase of the cells in the G2-phase (22%) and in aneuploidy (total 14%) 
compared to p53-proficient A549 cells (7.5% and 1.8%, respectively) (Fig. 3), which 
is in agreement with the dominant role of p53 in the induction of the G1-arrest (28). 
The dominant role of p53 in protection from aneuploidy is highlighted by the finding 
that additional inhibition of REV3 expression in combination with inhibition of p53 
expression did not further increase aneuploidy in A549 cancer cells.  
 
7.5. Discussion 
Mutations acquired during tumor development can render cancer cells reliant on a 
reduced set of DNA repair pathways for survival (reviewed in (29)). During our study 
on the involvement of REV3 in chemotherapy response we found that lentiviral-based 
inhibition of REV3 expression was as efficient in the normal as in the cancer cell lines 
but surprisingly colony formation was reduced in the cancer cell lines only. Therefore, 
we conclude that reduction in colony formation does not simply mirror the degree of 
REV3 expression inhibition relative to scrambled control.  
We found that colony formation was not significantly reduced in the normal cell line 
AD293 and the primary mesothelial cultures SDM104 and LP9-hTERT after inhibition 
of REV3 expression. This is consistent with previous studies where no deficiency in 
cell growth/survival was mentioned after antisense-based inhibition of REV3 
expression in human non-tumor cell lines (10, 30). In contrast, it was shown by 
different groups that REV3 knockout reduced cell growth of MEFs (13, 31). Thus, 
additional studies will be necessary to clarify how normal cells adapt their DDR to 
tolerate the loss of REV3 function.  
Studies have shown controversial results on the effect of REV3 inhibition on cancer 
cell growth. On one hand, no deficiency in cell growth/survival was mentioned after 
si/shRNA-based inhibition of REV3 expression in HCT116, U2OS and HeLa cancer 
cells (8, 32, 33). On the other hand it was shown that knockout of REV3 resulted in a 
pronounced growth retardation in Burkitt’s Lymphoma cells (34). We found that 
inhibition of REV3 expression per se reduced colony formation in lung, breast, 
mesothelioma and colon tumor cell lines. There are two possible explanations for 
these apparently controversial observations on the effects of inhibition of REV3 
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expression in cancer cells. First, when investigated, it was found that inhibition of 
REV3 expression per se increased DNA damage levels in cancer cells even when no 
effect on cell growth/survival was mentioned (8, 33, 34). Thus, it is possible that the 
DNA damage level necessary for DDR activation is different in the tested cell lines, 
explaining the presence or absence of growth arrest. Second, the effect of inhibition 
of REV3 expression may depend on the genetic modifications acquired during clonal 
selection or the genetic background. 
The first possibility is illustrated by the fact that only inhibition of REV3 expression by 
high-titer transduction resulted in a reduction of colony formation in MMR-deficient 
HCT116 cells although REV3 expression was not further reduced. It was shown 
before that activation of the DDR is impaired in MMR-deficient HCT116 cells (35). 
Thus, a higher level of cellular stress in form of additional DNA double strand breaks 
due to more viral integration events after high-titer transduction might be required in 
HCT116 cells for the induction of a DDR resulting in the reduced colony formation 
after inhibition of REV3 expression.  
Additionally, p53 status has an influence on the outcome of inhibition of REV3 
expression. The p53 status did not affect the accumulation of persistent DNA double 
strand breaks indicated by P-ATM foci after inhibition of REV3 expression in HCT116 
cells. Similarly, a recent study showed that DNA damage accumulation after 
prolonged activation of the mitotic checkpoint is also independent of the p53 status 
(36). Thus, p53 does not protect cancer cells from damage accumulation due to 
inhibition of REV3 expression although the subsequent cell-fate, as discussed below, 
is dependent on the p53-status.  
Cellular senescence serves to limit the proliferation of damaged cells that are at risk 
for neoplastic transformation (reviewed in (27)). Our data indicates that, at least in 
p53-proficient cancer cells, senescence induction after inhibition of REV3 expression 
might prevent further transformation of cancer cells by establishing an essentially 
irreversible growth arrest. It is also proposed that the senescence-associated 
secretory phenotype, which we observed after inhibition of REV3 expression 
indicated by increased IL-6 secretion, might stimulate the immune system to clear 
senescent cells (reviewed in (27)). However, if senescent cells are not cleared by the 
immune system, they remain in a “dormant” state representing a dangerous potential 
for tumor relapse.  
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A recent study showed that nocodazole (a microtubule polymerization inhibitor) 
treatment of p53-deficient HCT116 cells leads to prolonged mitosis and subsequent 
return of the mitotically arrested cells to interphase without cell division resulted in 
aneuploidy (36), a process known as mitotic slippage. We observed that inhibition of 
REV3 expression in the p53-deficient HCT116 cell line and in combination with p53 
inhibition in the A549 cell line leads to an accumulation of G2/M-arrested cells and an 
increase in the frequency of aneuploid cells as it was also described in p53-deficient 
REV3-null MEFs (31).  
Assuming that REV3 has a major function in the regulation of the spindle checkpoint, 
we would expect that inhibition of REV3 expression in normal cells results in a 
significant G2/M-arrest and the accumulation of aneuploid cells as observed after 
MAD2 inhibition (37), which was not observed in this study. Thus, we infer that the 
senescence induction or occurrence of aneuploidy after inhibition of REV3 
expression does not result from a deficiency in spindle checkpoint regulation due to 
inhibition of REV3 expression. 
Based on these results we propose a model (Figure 5) in which inhibition of REV3 
expression can be tolerated in normal cells but results in the accumulation of 
persistent DNA damage in cancer cells harbouring cancer-specific alterations. 
Accumulation of persistent DNA damage leads in p53-proficient cancer cells to 
senescence whereas inhibition of REV3 expression in p53-deficient cells results in 
growth inhibition and a G2/M-arrest. A small fraction of the p53-deficient cancer cells 
can overcome the G2/M-arrest, which results in mitotic slippage and aneuploidy.  
The concept of “synthetic lethality”, where defects in two pathways alone can be 
tolerated but become lethal when combined, has been originally described in 
Drosophila and yeast genetic studies (38, 39). This concept has been extended by 
the idea of “synthetic sickness”, whereas the combined loss/mutation of function of 
two genes does not kill cells but significantly impairs cellular fitness (40). 
A recent study showed that inhibiting DNA replication Pol β and Pol γ induces 
synthetic sickness/lethality specifically in MMR-deficient cells (41). We assume that 
inhibition of REV3 expression in cancer cells induces synthetic sickness/lethality in 
the presence of yet-to-be identified cancer-specific modifications. For example, DNA 
repair- and/or cell cycle checkpoint mechanisms are frequently abrogated in cancer 
cells (42) and the concentration of endogenous DNA damage is higher in human 
tumoral tissue compared to corresponding adjacent normal tissue (reviewed in (43)). 
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Therefore, differences in repair capacity or DNA damage levels between normal and 
cancer cells might be the underlying cause for the observed increased sensitivity of 
cancer cells to inhibition of REV3 expression. Alternatively, replication stress due to 
the activation of oncogenes might sensitize cancer cells to inhibition of REV3 
expression. A recent study showed that over-expression of Sch9, the S. cerevisiae 
homologue of the mammalian proto-oncogenes Akt and S6, increases superoxide-
dependent DNA damage, which subsequently leads to the REV3-dependent 
formation of point mutations to avoid gross chromosomal rearrangements (44). It will 
be interesting to identify the cancer-specific alteration(s) responsible for the observed 
induction of synthetic sickness/lethality by inhibition of REV3 expression.  
Cancer cells can not only be addicted to oncogenes but also to non-oncogenes 
(reviewed in (45)). “Non-oncogene addiction” genes are also required for 
maintenance of the tumorigenic state but are in contrast to oncogenes not 
functionally altered or mutated. The most prominent example of a “non-oncogene 
addiction” gene is PARP, which is essential in BRCA-deficient breast cancer cells. 
Thus, based on the results of our study we propose that REV3 functions as a “non-
oncogene addiction” gene, whose inhibition induces synthetic sickness/lethality 
specifically in cancer cells. It will be interesting to determine if (1) DNA damage 
tolerance by REV3-dependent TLS, (2) REV3-dependent DNA repair or (3) a yet-to-
be identified function of REV3 is essential for cancer growth. Indeed, the size of 
mammalian REV3 is approximately double the size of the yeast homologue giving 
rise to the possibility that the non-conserved region of REV3 harbors a yet-to-be 
identified functional domain, necessary only in higher organisms. 
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7.7. Figure Legends 
 
 
 
 
Figure 1. Inhibition of REV3 expression specifically reduces colony formation 
of cancer cell lines. Cells were mock treated or transduced with lentiviral-based 
particles containing either shSCR or shREV3. (A and B) Cells were stained by crystal 
violet and total colonies were counted after 2-4 weeks. Colonies were counted from 
at least 3 independent experiments for all cell lines. Colony number of mock treated 
cells were set as 100% (*p< 0.05; **p< 0.01). Shown are means +/- standard error of 
the mean (SEM). 
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Figure 2. Inhibition of REV3 expression induces persistent DNA damage and 
chromosomal instability specifically in cancer cells. Cells were mock treated or 
transduced with lentiviral-based particles containing either shSCR or shREV3 and 
analyzed after 1 week. (A) Cells were stained for P-ATM, γH2AX or BrdU (all green) 
and 53BP1 (red) and quantified by immunofluorescence microscopy. Cells containing 
more than 2 53BP1 foci were considered as 53BP1 positive. (B) Cells were stained 
for P-ATM and foci were quantified by immunofluorescence microscopy. (C) Cells 
were stained for γH2AX (green) and micronuclei formation was quantified by 
immunofluorescence microscopy. Nuclear DNA was labeled with DAPI (blue). At 
least 3 independent experiments were analyzed (*p< 0.05; **p< 0.01). Shown are 
means +/- SEM. 
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Figure 3. Inhibition of REV3 expression changes cell cycle distribution of 
cancer cell lines. Cells were mock treated or transduced with lentiviral-based 
particles containing either shSCR or shREV3 and/or lentiviral-based particles 
containing shP53. After one week, cell cycle distribution was measured by BrdU/PI 
staining and subsequent FACS analysis. The averages of 3 independent 
experiments are given for A549, A549 shP53, p53-proficient HCT116 and p53-
deficient HCT116 cells whereas representative experiments are shown for SDM104 
and AD293 cells (*p< 0.05; **p< 0.01). (AD: aneuploid dividing cells; AN: aneuploid 
non dividing cells). Shown are means +/- SEM. 
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Figure 4. Inhibition of REV3 expression induces DNA damage response 
pathway in cancer cells. Cells were cisplatin- or mock treated or transduced with 
lentiviral-based particles containing either shSCR or shREV3. (A) After one week, 
whole cell lysates were analyzed by western analysis. (B) After 24 hours IL-6 
secretion in serum-free DMEM was assessed by ELISA, normalized to the cell 
number and reported as pg/ml. The averages of 3 independent experiments are 
given. Shown are means +/- SEM. 
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Figure 5. Model: Cancer cells are addicted to REV3. See text for details. 
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7.8. Supporting Information 
7.8.1. Supplementary Figures 
 
Figure S1. Efficient inhibition of REV3 expression after transduction with 
lentiviral-based particles. Cells were mock treated or transduced with lentiviral-
based particles containing either shSCR or shREV3 and/or lentiviral-based particles 
containing shP53. REV3 (A and B) and P53 (C) expression were analyzed by 
quantitative real time PCR 7 days after transduction. The averages of at least 3 
independent experiments are given for A549, IL45, p53-proficient HCT116, p53-
deficient HCT116, SDM104 and AD293 cells whereas representative experiments 
are shown for Calu-3, MDA-MB231, MCF-7, ZL55 and LP9/hTert cells. Rev3 
expression levels were normalized to histone H3 expression levels. All Rev3 and p53 
expression levels are reported as percentage compared to mock treated A549 (A and 
C) or p53-proficient HCT116 (B) cells which was set as 100%. Shown are means +/- 
standard error of the mean (SEM). 
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Figure S2. Inhibition of REV3 expression specifically reduces colony formation 
of cancer cells. Cancer cells A549, IL45, MDA-MB231, p53-proficient HCT116, p53-
deficient HCT116 and normal cells AD293 were either mock treated or transduced 
with lentiviral-based particles containing shSCR or shREV3. Crystal violet staining 
was performed once colonies were visible by eye. (A) MOI170 (B) MOI 800. 
Experiments were made in duplicate wells. See also related Fig.1  
 
 
Figure S3. Reduced colony formation after inhibition of REV3 expression is not 
due to a siRNA off-target effect. IL45 mesothelioma cancer cells and AD293normal 
cells were either mock treated or transfected with three different plasmids containing 
shRNA-constructs targeting Rev3. Colonies were stained with crystal violet and 
counted after 2 weeks. Experiment was made in duplicate wells. 
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Figure S4. Inhibition of REV3 expression induces senescence in p53-proficient 
cancer cells. Cancer cells A549, IL45, MDA-MB231, p53-proficient HCT116 and 
p53-deficient HCT116 and normal cells AD293 were mock treated or transduced with 
either lentiviral-based particles containing shSCR or shREV3. Crystal violet assay 
(upper lines) or SA-β-galactosidase assay (bottom lines) was performed after 7 days.  
 
7.8.2 Supplementary Materials and Methods 
Cell Lines 
The human MPM cell line ZL55 and the primary cell culture SDM104 were generated 
in our laboratory (46, 47). The rat MPM cell line IL45 was generated elsewhere (48). 
The breast cancer cell lines MDA-MB231 and MCF-7, the adenocarcinoma Calu-3, 
the squamous NSCLC A549 and the HEK293T were purchased from ATCC. The 
AD293 cell line, a HEK293 derivative with improved cell adherence, was purchased 
from Stratagene. The colorectal carcinoma cell lines HCT116 40.16 (p53+/+) and 
HCT116 379.2 (p53-/-) were kindly provided by Dr. Bert Vogelstein (Johns Hopkins 
University, Baltimore, MD). 
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Reagents 
When indicated, 20 µM cisplatin (Ebewe) was added for 24 hours. 
To clone the short hairpin constructs into the plasmid pSuperior.puro, the following 
DNA oligonucleotides were ordered from Microsynth: 
shREV3-4: 
5’-
GATCCCCCAAAGATGCTGCTACATTATTCAAGAGATAATGTAGCAGCATCTTTGT
TTTTA-3’ 
5’-
AGCTTAAAAACAAAGATGCTGCTACATTATCTCTTGAATAATGTAGCAGCATCTTT
GGGG-3’ 
shREV3-5: 
5’- 
GATCCCCGATATTCCATCTGTTACAATTCAAGAGATTGTAACAGATGGAATATCT
TTTTA-3’ 
5’-
AGCTTAAAAAGATATTCCATCTGTTACAATCTCTTGAATTGTAACAGATGGAATAT
CGGG-3’ 
shREV3-6: 
5’-
GATCCCCTAGTCAGACTTTTCAGCCTTTCAAGAGAAGGCTGAAAAGTCTGACTAT
TTTTA-3’ 
5’-
AGCTTAAAAATAGTCAGACTTTTCAGCCTTCTCTTGAAAGGCTGAAAAGTCTGAC
TAGGG-3’ 
shSCR: 
5’-
GATCCCCATTCTAGGTGAAAGCTAATTTCAAGAGATAAGATCCACTTTCGATTAT
TTTTA-3’ 
5’-
AGCTTAAAAATAATCGAAAGTGGATCTTATCTCTTGAAATTAGCTTTCACCTAGAA
TGGG-3’ 
shP53: 
81 
5’- 
GATCCCCGACTCCAGTGGTAATCTACTTCAAGAGAGTAGATTACCACTGGAGTC
TTTTTA-3’ 
5’-
AGCTTAAAAAGACTCCAGTGGTAATCTACTCTCTTGAAGTAGATTACCACTGGAG
TCGGG-3’ 
 
To quantitatively measure the expression of REV3 mRNA by real time PCR, the 
following DNA oligonucleotides were ordered from Microsynth: 
REV3 forward   5’-TGAGTTCAAATTTGGCTGTACCT-3’ 
REV3 reverse   5’-TCTAGTCTTCAAAATTTCTTCAAGCA-3’ 
Histone H3 forward  5’-TAAAGCACCCAGGAAACAACTGGC-3’ 
Histone H3 reverse  5’-ACCAGGCCTGTAACGATGAGGTTT-3’ 
P53 forward   5’- GCTTTGAGGTTCGTGTTTGTGCCT-3’ 
P53 reverse   5’-GCCCACGGATCTTAAGGGTGAAAT-3’ 
 
For western analysis, the following primary antibodies were diluted 1:1000: PARP 
(Cell Signaling #9542), P-Chk2 (R&D Systems #AF1626), p53 (Cell Signaling 
#9282), p21 (Santa Cruz #sc-756), cyclin E (Santa Cruz #sc247), MAD2B/Rev7 (BD 
Biosciences #612266). The primary antibody β-Actin (MP Biomedicals #691001) was 
incubated 1:10’000 for 1 hour at room temperature. The secondary polyclonal 
antibodies coupled to horseradish peroxidase (HRP) were diluted 1:10’000.  
For immunofluorescence microscopy, the following primary antibodies were used: P-
ATM 1:1000 (Cell Signaling #sc4526), γH2AX 1:1000 (Upstate #05-636), 53BP1 
1:500 (Cell Signalling #4937) and BrdU 1:1000 (BD Biosciences #555627). 
Vector Production and Transduction 
Short hairpin REV3-4 and scrambled (shSCR) oligos were ligated into pSuperior.puro 
as described by the manufacturer (OligoEngine). The shRNA and H1 promoter 
fragments were subsequently ligated into the constitutive expressing lentiviral vector 
pLVTHM (Addgene). Replication-deficient lentiviral particles were produced and 
titrated as described previously (20, 21). 
Cells were seeded in six-well plates (colony formation, immunofluorescence and 
senescence associated (SA) Βeta-galactosidase assay: 500 cells/well [SDM104: 
1000 cells/well]; FACS and western analysis: 2500 cells/well [SDM104: 5000 
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cells/well]; Realtime-polychain reaction (RT-PCR) and ELISA: 5000 cells/well) in 2ml 
medium. After 6 hours medium was removed and lentivirus suspension added for 30 
minutes in 300μl (Immunofluorescence, FACS and RT-PCR multiplicity of infection 
(MOI) 100; Western analysis and colony formation: MOI 170). All transductions of 
HCT116- and corresponding control AD293 cells were performed with an MOI800 
and incubated for 1 hour. Subsequently, medium was added to final volume of 1.5 
ml. For mock treatment, 0.5μm-filtered conditioned medium from a HEK293T culture 
was added. After 7 days, cells were further processed for distinct experiment as 
described below except for colony formation, which were incubated longer as 
described below. 
Quantitative Real-Time PCR 
Real time PCR cycle conditions were as follows: 1 cycle of 95°C for 10 minutes, 40 
cycles of 95°C for 15 seconds and 60°C for 1 minute and 1 cycle of 95°C for 15 
seconds and from 60°C slowly elevating to 95°C over several minutes for 
dissociation curve analysis. Histone H3 expression was used to standardize the total 
amount of cDNA and the specificity of the PCR reaction was confirmed by analysis of 
the melting curve.  
Immunofluorescence microscopy 
Immunofluorescence microscopy was performed essentially as described before 
(22). In detail, for BrdU staining, cells were incubated with 10 μM BrdU for 1 hour. 
Fixation and permeabilization was done with 100% Methanol -20°C and 
Acetone:Methanol (50:50) -20°C for 20 min at room temperature, respectively. Cells 
were washed 2x5 min with PBS. For BrdU staining, cells were denatured with 2M 
HCl for 30min at room temperature and subsequently washed 3x5 min with PBS. 
PBS containing 1% FBS and 10% BSA was used as blocking solution for 1hour at 
room temperature. First antibodies were diluted in blocking solution and incubated at 
4°C over night. Following antibodies were used: P-ATM 1:1000 (Cell Signaling 
#sc4526), γH2AX 1:1000 (Upstate #05-636), 53BP1 1:500 (Cell Signalling #4937) 
and BrdU 1:1000 (BD Biosciences #555627). Cells were washed 2x5 min in PBS. 
Secondary antibodies were 1:10000 diluted in blocking solution and incubated at 37 
°C for 1 hour. Cells were washed 2x5min with PBS and mounted with ProLong Gold 
Antifade reagent with DAPI (Invitrogen #P36931). Images were acquired with an 
inverse wide field fluorescence microscope (Leica DM IRBE) equipped with a black 
and white camera (Hamamatsu ORKA-ER). Image processing with Photoshop 
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(Adobe Systems) was applied to whole images only. Images used for comparison 
between different transductions were acquired with the same instrument settings and 
exposure time and were processed equally. 
Flow Cytometry 
Cell cycle distribution was assed by using a FACSCalibur (FACScan, BD 
Biosciences, 488 nm excitation laser) and WinMDI software. 
Western analysis 
Cells were lysed for 30 min on ice in 1× RIPA buffer (Upstate) containing 2xHALTTM 
protease and phosphatase inhibitor cocktail (Thermo scientific). Cell extracts were 
denatured at 95°C for 5 minutes, homogenized by successive passing through a 30-
gauge syringe needle and protein concentrations were determined using BCA protein 
assay (Pierce). 
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